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ABSTRACT 
Members of the TNF receptor superfamily, many of which are important for 
immune and inflammatory responses, have been shown to utilize ubiquitination for signal 
transduction. Two proteins, cellular inhibitor of apoptosis proteins 1 and 2 (c-IAP1/2), 
play central roles in the signaling cascades from these receptors through their ubiquitin 
ligase activity. In certain pathways, c-IAP1/2 actively propagate receptor-mediated 
signaling through the construction of ubiquitin scaffolds within the receptor signaling 
complex, while in other situations, c-IAP1/2 constitutively target substrate proteins for 
ubiquitination and degradation, inhibiting signal transduction. Activation of these 
signaling pathways is dependent on the degradation of c-IAP1/2, a process that is 
associated with stimulation of specific members of the TNF receptor superfamily. While 
the biological properties of c-IAP1/2 are context-dependent, the exact roles and outcomes 
of c-IAP1/2 activity in these different circumstances are unclear. In the work presented in 
this dissertation, these diverse roles of c-IAP1/2 in signaling were further explored, 
characterizing the signaling pathways in which they participate, investigating their 
regulation, and identifying the downstream consequences of their activity. Using multiple 
methods to study the function of c-IAP1/2, including activation of TNF receptor 
superfamily members and treatment with synthetic compounds that target and degrade c-
IAP1/2, novel aspects of c-IAP1/2 activity in signaling were characterized. Specifically, 
the regulation of canonical and non-canonical NF-kappa B activation by c-IAP1/2 was 
investigated, finding that the consequences of c-IAP1/2 activity were cell type-specific. 
 xii 
Furthermore, important regulatory crosstalk between the NF-kappa B signaling pathways 
was identified in cells that activated both canonical and non-canonical NF-kappa B. 
Additionally, novel roles for c-IAP1/2 were identified using transcriptome analysis and a 
technique called Bru-seq, and these roles included the regulation of ribosomal gene 
expression and protein synthesis. These results may have important clinical implications, 
since the IAPs are actively being studied as potential therapeutic targets. Collectively, 
these findings expand our understanding of ubiquitin-dependent signaling and, more 
specifically, provide crucial insight into the multifaceted functions of c-IAP1 and c-IAP2 
in key intracellular signaling pathways. 
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 CHAPTER I
Introduction 
 
The Inhibitor of Apoptosis Protein Family 
Control of cellular fate is vital for developing and maintaining a properly 
functioning immune system. Proper regulation of cell death is necessary for producing 
functional immune cell repertoires, eliminating infected cells, and contraction of the 
effector cell populations following termination of the immune response (Cohen and 
Duke, 1992). Additionally, evasion of cell death is a known characteristic of cancer and 
has been the focus of numerous therapeutic strategies (Hanahan and Weinberg, 2011). 
The study of cell death and its regulation led to the discovery and characterization of a 
family of factors called the inhibitor of apoptosis (IAP) proteins, and over the last few 
decades, the IAP protein family has been found to play major roles in a multitude of 
cellular processes. The first IAP was discovered in 1993 through a gene complementation 
assay (Crook et al., 1993) and was found to prevent baculovirus-induced cell death in 
insect cells. Furthermore, sequence analysis showed that the iap gene encoded for a zinc 
finger-like motif, dubbed a baculovirus IAP repeat (BIR) domain (Clem and Miller, 
1994), and homology studies identified iap genes in the genomes of multiple species, 
including yeast, nematodes, fruit flies, and humans, indicating that these genes were 
highly evolutionarily conserved (Uren et al., 1999; Fraser et al., 1999; Hay et al., 1995; 
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Rothe et al., 1995; Uren et al., 1996; Roy et al., 1995; Liston et al., 1996; Duckett et al., 
1996). 
The mammalian IAP family consists of eight members, all of which share the 
family-defining BIR domain (Fig. 1.1), and while every IAP member possesses at least 
one BIR domain, many members contain multiple BIR domains. Three of the best 
characterized IAPs are x-linked IAP (XIAP), cellular IAP 1 (c-IAP1), and cellular IAP 2 
(c-IAP2), each of which possess three BIR domains (Fig. 1.1) that are responsible for 
protein-protein interactions between the IAPs and other factors, such as caspases (Scott et 
al., 2005; Wilkinson et al., 2008). In addition to the BIR domains, XIAP and the c-IAPs 
contain a carboxy-terminal really interesting new gene (RING) domain, which confers E3 
ubiquitin ligase activity and plays an important role in the functional activities of these 
proteins (Fig. 1.1). The c-IAPs also contain two additional domains: a caspase-associated 
recruitment domain (CARD) and an ubiquitin-associated (UBA) domain (Fig. 1.1). While 
their exact functions remain unresolved, the CARD may allow the c-IAPs to interact with 
additional CARD-containing proteins and appears to regulate their E3 ubiquitin ligase 
activity (Lopez et al., 2011), and the UBA domain has been shown to bind ubiquitin and 
has recently been found to facilitate recruitment of other factors involved in the 
ubiquitination process (Budhidarmo and Day, 2014). 
Elevated expression of XIAP and c-IAP1 has been described in multiple cancer 
types, which has led to the targeting of the IAPs as a potential anti-cancer therapy. 
Additionally, high expression of certain IAPs has been correlated with poor survival rates 
in several cancers, including XIAP expression in colorectal cancer and diffuse large B 
cell lymphoma (Xiang et al., 2009; Hussain et al., 2010), c-IAP2 in pancreatic cancer and 
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colorectal cancer (Esposito et al., 2007; Krajewska et al., 2005), and c-IAP1 in cervical 
squamous cell carcinoma (Imoto et al., 2002). However, the precise role of the IAPs in 
the progression of cancer is still unclear and remains a focus of ongoing research. 
 
 
 
IAPs and Regulation of Cell Death 
The IAPs were originally described as regulators of cell death (Liu et al., 2000), a 
process that is vital in the development and maintenance of the immune system and its 
response to antigenic challenge. Furthermore, the ability to avoid cell death is a major 
characteristic of cancer (Hanahan and Weinberg, 2000). While many forms of cell death 
have been described (Ashkenazi and Salvesen, 2014; Danial and Korsmeyer, 2004), the 
XIAP
c-IAP2
c-IAP1
BIR: CARD: RING:UBA:
hILP-2
ML-IAP
NAIP
Survivin
Apollon
Figure 1.1 Schematic depiction of the inhibitor of apoptosis (IAP) protein family. 
BIR, baculovirus IAP repeat; CARD, caspase-associated recruitment domain; UBA, 
ubiquitin-associated domain; RING, really interesting new gene. 
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best-characterized type of cell death is apoptosis. Apoptosis, sometimes referred to as 
programmed cell death, is a highly regulated process that progresses through a series of 
clearly defined cellular events, including caspase activation, cell membrane blebbing, and 
fragmentation of chromosomal DNA, and can be initiated by a multitude of cues 
(Ashkenazi and Salvesen, 2014). Importantly, apoptosis, unlike other forms of cell death, 
is generally non-inflammatory, and this is because the process of apoptosis fragments the 
cell in a way in which the resulting apoptotic bodies are easily and quickly removed by 
phagocytic cells prior to the release of cellular components that can elicit an 
inflammatory response through a process called efferocytosis (Korns et al., 2011). 
Apoptosis is important in the regulation of cancer progression and in normal 
development, including development and maintenance of the immune system, as well as 
during the immune response. For example, apoptosis is vital for the proper development 
of the T and B cell repertoire (Cohen and Duke, 1992), and cells that undergo 
nonproductive gene rearrangement and fail to produce a functional T cell receptor or B 
cell receptor are eliminated by apoptosis. Similarly, autoreactive cells are deleted by 
apoptosis during development and maturation (Marrack and Kappler, 2004). During the 
immune response, cytotoxic T cells and NK cells induce apoptosis in infected cells 
(Shresta et al., 1998), and following the clearance of pathogen, the expanded effector cell 
population is contracted through the induction of apoptosis (Cohen and Duke, 1992).  
There are two major signaling cascades leading to apoptosis, the intrinsic and 
extrinsic death pathways, which are classified based on their distinct sources of lethal 
stimuli. The intrinsic cell death pathway is initiated by intracellular insults such as 
starvation, ultraviolet irradiation, chemotherapeutic drugs, and lack of necessary growth 
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factors (Tait and Green, 2010). Central to the intrinsic death pathway is the control of the 
structural integrity of the mitochondria. Major regulators of this event are the members of 
the B cell lymphoma-2 (Bcl-2) protein family, which can be categorized into two major 
groups: factors that promote apoptosis and those that inhibit apoptosis (Youle and 
Strasser, 2008). Following an apoptotic signal, the anti-apoptotic proteins Bcl-2 and Bcl-
x long (Bcl-xL) are sequestered by pro-apoptotic members of the Bcl-2 family, which 
allows the pro-apoptotic Bcl-2 proteins Bcl-2-antagonist/killer-1 (Bak) and Bcl-2-
associated X protein (Bax) to oligomerize and insert themselves into the outer membrane 
of the mitochondria, forming a pore-like structure (Fig. 1.2) (Tait and Green, 2010). Once 
formed, these structures allow for the rapid release of components held in the inter-
membrane space of the mitochondria, such as second mitochondrial activator of 
caspases/direct IAP binding protein with low pI (Smac/DIABLO), through an event 
known as mitochondrial outer membrane permeabilization, or MOMP (Tait and Green, 
2010). Cytochrome c, a component of the electron transport chain, is also released from 
the mitochondria during this process (Ow et al., 2008), and once in the cytoplasm, 
cytochrome c binds to apoptotic protease activating factor-1 (Apaf-1) and pro-caspase-9 
to form a structure called the apoptosome (Fig. 1.2). This complex activates caspase-9, 
which proceeds to cleave and activate the downstream effector caspases and subsequently 
results in cell death (Tait and Green, 2010). 
The extrinsic pathway, in contrast, is death receptor-mediated, wherein a ligand 
binds a death receptor, such as Fas, on the surface of the cell. Binding of the trimeric 
ligand induces the trimerization of the receptor, which subsequently recruits the Fas-
associated via death domain (FADD) protein. FADD, through its death domain (DD), 
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binds to DD within the cytoplasmic tail of the receptor (Park et al., 2007). Additionally, 
FADD contains a death effector domain (DED), which recruits pro-caspase-8 to the 
forming receptor signaling complex (Park et al., 2007). This FADD:caspase complex is 
oftentimes referred to as the death inducing signaling complex (DISC). In certain cells, 
termed Type I cells, the active caspases in the DISC proceed to directly cleave and 
activate downstream caspases, including caspase-3 and caspase-7, which then execute the 
cellular changes associated with apoptosis (Fig. 1.2) (Scaffidi et al., 1998). More 
commonly, however, cells require additional pro-apoptotic signals from the 
mitochondria. The extrinsic death pathway in these cells, called Type II cells, therefore 
overlaps significantly with signaling machinery of the intrinsic cell death pathway 
(Scaffidi et al., 1998). In these cells, formation of the DISC results in the caspase-8-
mediated cleavage of a protein called Bcl-2 homology 3-interacting domain death agonist 
(Bid) to generate truncated Bid (tBid), which proceeds to initiate Bax/Bak 
oligomerization and results in MOMP, apoptosome formation, effector caspase 
activation, and eventually cell death (Fig. 1.2) (Wei et al., 2000; Eskes et al., 2000). 
As described above, the IAPs were originally thought to regulate apoptosis 
through the inhibition of caspases. XIAP is the archetypical IAP protein that directly 
binds and inhibits caspases, specifically caspase-3, caspase-7, and caspase-9, preventing 
their downstream effector functions (Deveraux et al., 1998; Deveraux et al., 1997). This 
binding occurs through the BIR domains of XIAP and has been shown to inhibit cell 
death (Salvesen and Duckett, 2002; Duckett et al., 1998). Due to this described role, 
members of the IAP protein family have been generally considered direct inhibitors of 
cell death. However, the caspase inhibition exhibited by XIAP is suppressed following 
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the initiation of the mitochondria-dependent apoptotic pathways. When MOMP occurs, 
cytochrome c release is accompanied by the release of other mitochondrial proteins into 
the cytoplasm, including Smac and the serine protease Omi/HtrA2 (Tait and Green, 
2010). These proteins possess IAP binding motifs (IBMs) and bind to XIAP in a manner 
that liberates the caspases, allowing them to be activated (Fig. 1.2). Furthermore, the IAP 
binding proteins can induce the ubiquitination and subsequent proteasome-dependent 
degradation of the bound IAPs (Csomos et al., 2009). 
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It has been demonstrated that Smac is capable of binding c-IAP1/2, inducing their 
autoubiquitination and degradation (Samuel et al., 2006; Yang and Du, 2004; Du et al., 
2000; Wu et al., 2000; Csomos et al., 2009). However, unlike XIAP, the c-IAPs do not 
Figure 1.2 The intrinsic and extrinsic apoptotic pathways. The intrinsic cell death 
pathway is initiated by an intracellular death signal. This signal results in the 
oligomerization and translocation of Bax and Bak into the outer membrane of the 
mitochondria. This triggers mitochondrial outer membrane permeabilization (MOMP) 
and the release of cytochrome c and IAP binding proteins. Cytochrome c forms the 
apoptosome with Apaf-1 and pro-caspase-9, which results in cell death. The IAP 
binding proteins, such as Smac, bind to XIAP and antagonize the caspase-binding 
function of XIAP. The extrinsic cell death pathway is receptor-mediated and results in 
the formation of the death inducing signaling complex (DISC). In certain cells, the 
DISC can directly activate downstream caspases, leading to cell death. However, in 
most cells, the DISC, through its caspase-8 component, cleaves Bid to form tBid, 
leading to Bax/Bak oligomerization, MOMP, apoptosome formation, and subsequent 
cell death. 
Extrinsic Death 
Signal
Caspase-8
Bid
tBid
Bax Bak
Intrinsic Death 
Signal
Bcl-xL
MOMPSmac
Omi
XIAP
Cyt C
Pro-Caspase-9
Apaf-1
Apoptosome 
Formation
Caspase Activation 
& Apoptosis
Cell Membrane
DISC 
Formation
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possess the ability to inhibit the apoptotic functions of caspases, despite their ability to 
bind caspases (Eckelman and Salvesen, 2006). This suggested that the c-IAPs might 
regulate cell death through other mechanisms. Recent work has implicated the c-IAPs in 
regulating other cell death-activating platforms. If the c-IAPs are removed by chemical, 
physiological, or genetic means, stimulation of tumor necrosis factor-receptor 1 (TNF-
R1) forms a complex containing FADD, active caspase-8, and receptor-interacting 
serine/threonine protein kinase 1 (RIP1) to induce apoptosis (Silke and Brink, 2010). 
Additionally, the c-IAPs have been associated in a recently described form of cell death, 
designated necroptosis, which exhibits hallmarks of both apoptosis and the inflammation-
inducing necrosis and occurs following the chemical degradation of the c-IAPs in 
conjunction with the inhibition of caspases (Feoktistova et al., 2011; Tenev et al., 2011). 
The death-activating platform involved in this pathway is called the ripoptosome and is 
comprised of RIP1, FADD, inactive caspase-8, and RIP3, a related protein to RIP1 
(Feoktistova et al., 2011; Tenev et al., 2011). The formation of the ripoptosome is 
purportedly independent of receptor activation and is thought to occur in specific cases 
following genotoxic stress, certain inflammatory stimuli, and c-IAP degradation (Darding 
and Meier, 2012; Feoktistova et al., 2011; Tenev et al., 2011).  
As the body of research grows, it has become more apparent that the IAPs play 
important functions in a host of cellular processes beyond their initially described 
function of caspase and cell death inhibition, implying that caspase-binding may, 
perhaps, only represent a minor facet of the IAPs. As such, the IAPs have come to be 
recognized as important regulators of intracellular signaling cascades, specifically the 
activation of nuclear factor-κB (NF-κB). The c-IAPs, as well as XIAP, have been 
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implicated in multiple pathways of NF-κB activation (Gyrd-Hansen and Meier, 2010), a 
family of transcription factors that play vital roles in a variety of signaling relevant to 
immunology and cancer as will be described in more detail below. Therefore, NF-κB can 
be, at times, considered a counterbalance to the death promoting signals within a cell. 
Even though they are poor inhibitors of caspase activity, the c-IAPs may contribute to the 
determination of cell fate through their regulation of NF-κB.  
 
IAPs as Regulators of Cell Signaling 
The functional scope of the IAPs has expanded beyond caspase-binding and cell 
death inhibition. IAPs have been implicated in regulating intracellular copper levels 
(Burstein et al., 2004; Mufti et al., 2006; Brady et al., 2010), cell cycle regulation 
(Samuel et al., 2005; Cartier et al., 2011), and cell migration (Oberoi et al., 2012; 
Kenneth and Duckett, 2012), and have also been shown to be important signal 
transduction factors in a variety of receptor-mediated pathways, many of which activate 
NF-κB (Silke and Brink, 2010). 
As discussed above, several members of the IAP family, including the c-IAPs and 
XIAP, possess RING domains, which have been shown to be vital in many of the 
signaling cascades in which the IAPs participate. In these signaling pathways, the IAPs, 
through their RING domains, function as E3 ubiquitin ligases, which are the final 
component in the ubiquitination enzymatic cascade. As a whole, the ubiquitination 
process involves ubiquitin-activating (E1), ubiquitin-conjugating (E2), and ubiquitin-
ligating (E3) enzymes (Komander and Rape, 2012). The E1 enzyme is responsible for 
activating ubiquitin for the entire pool of downstream ubiquitin pathways (Heride et al., 
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2014; Pickart, 2001), while the E2 enzymes are able to bind with the ubiquitination target 
protein and the E3 ligase (Deshaies and Joazeiro, 2009). The process culminates with the 
E3 ligase transferring the ubiquitin molecule from the E2 to the target substrate, resulting 
in a covalently linked ubiquitinated substrate (Deshaies and Joazeiro, 2009). Through this 
process and in addition to monoubiquitination, polyubiquitin chains can be constructed, 
marking target proteins for a variety of subsequent functional outcomes. There are at least 
eight distinct polyubiquitin chains that can be formed within a cell, and these chains are 
defined by their linkages (Heride et al., 2014). Two well-studied polyubiquitin chains are 
the K63-linked chain and the K48-linked chain, defined by their linkages at specific 
lysines within ubiquitin (Heride et al., 2014), and the IAPs have been shown to mediate 
both K48 and K63 ubiquitination (Yang et al., 2000; Huang et al., 2000; Li et al., 2002; 
Varfolomeev et al., 2008; Bertrand et al., 2008). The K48 ubiquitin chain is generally 
considered to be a degradation signal that targets the marked protein for proteasome-
mediated destruction. In contrast, K63 polyubiquitination does not mediate proteasomal 
degradation, but rather acts as a scaffold for recruitment of additional factors to the 
signaling complex (Walczak, 2011). The c-IAPs are E3 ubiquitin ligases for multiple 
components in the NF-κB pathways, including RIP1 and NF-κB-inducing kinase (NIK), 
and the ability to mediate these forms of ubiquitination is integral to the functions of the 
IAPs in regulating the activation of NF-κB. 
NF-κB is a family of transcription factors that plays important functions in many 
cellular responses. The family is comprised of five members: p65 (RelA), RelB, c-Rel, 
p50 (NF-κB1), and p52 (NF-κB2), and following activation, these factors dimerize to 
form the active transcription factor (Hayden and Ghosh, 2008). There are at least ten 
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distinct dimers, which each have different transcriptional properties (Smale, 2012). Each 
NF-κB subunit possesses a Rel homology domain (RHD) that allows for the binding to 
κB elements within DNA, and p65, RelB, and c-Rel also have transcriptional activation 
domains (TADs), which are associated with active transcription (Vallabhapurapu and 
Karin, 2009). In contrast, p50 and p52 do not possess a TAD, and homodimers of these 
subunits appear to regulate transcription through different mechanisms (Vallabhapurapu 
and Karin, 2009). Prior to activation, NF-κB dimers are sequestered in the cytoplasm of 
the cell, rendered inactive through the binding of IκB proteins. These proteins mask the 
nuclear localization sequence in NF-κB and prevent DNA binding through their ankyrin 
repeats (Sun, 2012). While the IκB protein family consists of multiple members, the most 
well characterized member is IκBα. Additionally, the precursor proteins of p50 and p52, 
p105 and p100, respectively, also possess ankyrin repeats within their C-terminal region 
and play similar functions to the other IκB proteins (Perkins, 2007). These precursor 
proteins are processed, liberating p50 and p52 to dimerize and modulate transcription. 
Similarly, IκBα is ubiquitinated and subsequently degraded by the proteasome following 
inititiation of the signaling cascade, allowing the NF-κB dimer to translocate into the 
nucleus. 
The NF-κB pathways are activated by a multitude of stimuli and play important 
roles in cancer and the innate immune response. For example, the pattern recognition 
receptors, such as nucleotide-binding oligomerization domain-like receptors (NLRs), 
Toll-like receptors (TLRs), and retinoic acid-inducible gene 1-like receptors (RLRs), 
activate NF-κB following recognition of a pathogen (Oeckinghaus et al., 2011; 
Vallabhapurapu and Karin, 2009). Signaling involving the pro-inflammatory cytokine IL-
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1β is also dependent on NF-κB, and, once active, induces NF-κB to further propagate an 
inflammatory response (Barker et al., 2011). Additionally, carcinogens and other tumor 
promoters can activate NF-κB, promoting inflammation and contributing to 
tumorigenesis (Aggarwall, 2004; Hanahan and Weinberg, 2011). Furthermore, NF-κB 
has been demonstrated to have important roles in the adaptive arm of immunity, 
including T and B cell development and their responses to immunological challenges. 
The B cell receptor and the T cell receptor activate NF-κB following encounter with 
antigen, and mice lacking NF-κB subunits display impaired B and T cell responses 
(Beinke and Ley, 2004). Additionally, in NF-κB deficient mice, the development of 
lymphoid organs is severely impaired.  For example, mice lacking Nfkb2 or Relb exhibit 
significant disruption of the architecture of the spleen and abnormal lymph node 
organization (Weih et al., 1995; Weih and Caamano, 2003), and ablation of Nfkb2 or Relb 
also results in an increased incidence of T cell-mediated inflammatory disease (Weih et 
al., 1995; Zhu et al., 2006). In Nfkb1-/- mice, B cells fail to induce a proliferative response 
when exposed to lipopolysaccharide (LPS) and soluble CD40L (Snapper et al., 1996), 
and Nfkb1 is also needed for T cell proliferation following antigen stimulation (Zheng et 
al., 2001), and differentiation into effector subsets (Beinke and Ley, 2004). Additionally, 
it is now believed that NF-κB is involved in thymic selection and development of T cells, 
though its exact role is still unclear (Gerondakis et al., 2014).  
There are two major pathways of NF-κB signaling, the canonical pathway that 
involves the p65:p50 dimer and the non-canonical pathway that employs the RelB:p52 
dimer (Hayden and Ghosh, 2008). Canonical NF-κB can be activated by a wide variety of 
stimuli, some of which involve the IAPs, and the resulting signaling cascades converge 
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on the IκB kinase (IKK) complex (Perkins, 2007). This complex has three components: 
IKKα (IKK1), IKKβ (IKK2), and NF-κB essential modulator (NEMO, also known as 
IKKγ). IKKα and IKKβ are the kinase subunits of the complex, while NEMO is a 
regulatory factor (Scheidereit, 2006). Once activated, the IKK complex phosphorylates 
IκBα, triggering its subsequent ubiquitination and proteasome-mediated degradation. As 
described above, this allows the canonical NF-κB dimer to translocate to the nucleus and 
initiate transcription. Non-canonical NF-κB, which is activated by a more limited set of 
stimuli, relies on a protein called NF-κB-inducing kinase (NIK). Prior to stimulation, 
NIK is constitutively degraded by a c-IAP-containing complex (Vallabhapurapu et al., 
2008). Following activation, this complex is inhibited, resulting in an increase in NIK 
protein levels, which then leads to the activation of IKKα. IKKα phosphorylates the NF-
κB precursor protein p100 at Ser-866 and Ser-870 (Sun, 2012), resulting in its 
proteasome-dependent cleavage and generation of the active p52 subunit. The RelB:p52 
dimers can then translocate into the nucleus to modulate gene expression. While the IAPs 
have been shown to participate in a variety of NF-κB activation pathways, the c-IAPs 
have been implicated in the regulation of both canonical and non-canonical NF-κB 
following stimulation of members of the TNF receptor superfamily, playing both 
activating and inhibitory roles (Silke and Brink, 2010).  
 
The c-IAPs and the TNF Receptor Superfamily 
The TNF receptor superfamily is comprised of a multitude of receptors that play 
important roles in the immune response (Silke and Brink, 2010), and these receptors can 
be broadly characterized into two major subsets based on their structural domains. 
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Receptors such as Fas and TNF-R1, which can be widely expressed, possess death 
domains within their cytoplasmic tails (Wertz and Dixit, 2010). These domains allow the 
receptor to recruit other DD-containing factors, building a receptor complex that can 
induce a variety of signaling. These receptors have important roles in inflammation, 
hematopoiesis, and the immune response (Walczak, 2011). In contrast, there are TNF 
receptor superfamily members that do not possess death domains and instead recruit 
signaling cofactors via TRAF-binding domains. These domains allow for the recruitment 
of members of the TNF receptor-associated factor (TRAF) family (Silke and Brink, 
2010), and while TRAFs are implicated in signaling from both groups of receptors, direct 
TRAF binding to the receptor results in distinct consequences (Hacker et al., 2011). 
Additionally, the expression of these receptors is more limited, and many of these 
receptors are predominantly found on hematopoietic cells (Croft et al., 2012), and as 
such, many of these receptors have been shown to play important roles in immunity. 
Previous work has demonstrated that the survival of mature B cells is dependent on the B 
cell activating factor receptor (BAFF-R) (Claudio et al., 2002), and CD40 (TNFRSF5) 
has also been shown to have a critical role in the B cell-mediated immune response 
(Quezada et al., 2004; Elgueta et al., 2009; Coope et al., 2002). Likewise, T cells are also 
reliant on members of the TRAF-binding TNF receptor superfamily, which can be found 
on naïve, effector, and memory T cells (Croft, 2003). For example, CD27 (TNFRSF7) 
can be found on naïve, effector, and memory T cells and is believed to be involved in 
promoting the initial expansion of the naïve T cell population, potentially by regulating 
the cell cycle (Agematsu et al., 1994; Hendriks et al., 2000; Croft, 2003). OX40 
(TNFRSF4) is expressed on effector T cells, and its absence results in increased cell 
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death several days after T cell activation, suggesting that OX40 provides signals that 
promote the survival of effector T cells during the immune response (Rogers et al., 2001; 
Croft, 2003). CD30 (TNFRSF8), which will be discussed in more detail below, is also 
found on effector T cells and may provide additional co-stimulatory signals during the T 
cell response (Croft, 2003). 
CD30, a member of the direct TRAF-binding subset of the TNFR superfamily, 
can be expressed on a subset of activated T cells (Del Prete et al., 1995; Bowen et al., 
1996; Nakamura et al., 1997; Croft, 2003), and while the exact physiological role of the 
receptor is still unclear, the mechanism of CD30 signaling is more clearly understood. 
CD30 has been shown to activate both canonical and non-canonical NF-κB (Wright et al., 
2007; Csomos et al., 2009), as well as MAPK pathways (Younes and Aggarwall, 2003). 
Furthermore, prolonged stimulation of CD30 has been shown to induce cell cycle arrest 
(Wright et al., 2007; Buchan and Al-Shamkhani, 2012), and CD30 activation has been 
linked to both inducing apoptosis and promoting proliferation and survival (Croft, 2003; 
Wright et al., 2007). The cytoplasmic tail of CD30 contains two distinct TRAF binding 
domains, with residues 561-573 binding TRAFs 1, 2, 3, and 5, while residues 578-586 
specifically bind TRAFs 1 and 2 (Gedrich et al., 1996; Aizawa et al., 1997; Duckett et al., 
1997; Duckett and Thompson, 1997; Buchan and Al-Shamkhani, 2012). As discussed in 
more detail below, the TRAF binding domains are vital for the c-IAP-dependent 
regulation of NF-κB activation. However, CD30 has been shown to activate NF-κB in the 
absence of its TRAF binding domains, indicating that upstream regions of the 
cytoplasmic tail of CD30 may also contribute to signaling (Duckett et al., 1997; Buchan 
and Al-Shamkhani, 2012). While the exact physiological role of CD30 remains unclear, it 
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has been realized that CD30 is highly expressed on certain types of cancers, including 
anaplastic large cell lymphoma (ALCL), Hodgkin’s lymphoma, multiple myeloma, and 
certain T cell leukemias (Stein et al., 1985; Chiarle et al., 1999; Younes and Aggarwall, 
2003). Due to its association with certain cancers, recent work has used CD30 as a means 
to target antibody-drug conjugates to malignant cells (Younes et al., 2010; Foyil and 
Bartlett, 2011). However, the full scope of the consequences of CD30-mediated NF-κB 
activation and its relationship to disease progression remains to be investigated. 
The c-IAPs are important factors in signaling from both categories of the TNF 
receptor superfamily, playing distinct roles for each subset of the superfamily. In the 
context of NF-κB activation by TNF-R1, a DD-containing receptor, the c-IAPs actively 
participate in the recruitment of proteins for signal transduction. Upon ligand binding to 
TNF-R1, the adaptor molecule TNF-R1-associated death domain protein (TRADD) is 
recruited to the DD of TNF-R1 (Hsu et al., 1995). TRADD binding, in turn, recruits 
additional proteins, including TRAF2, c-IAP1/2, and RIP1 to form the initial receptor 
signaling complex (Fig 1.3) (Hsu et al., 1996a; Hsu et al., 1996b; Shu et al., 1996; 
Micheau and Tschopp, 2003; Vince et al., 2009). The c-IAPs polyubiquitinate RIP1 in a 
K63-dependent manner, forming a scaffold for the recruitment of additional factors, 
including transforming growth factor-β activating kinase 1 (TAK1), TAK1 binding 
protein 2 (TAB2), and TAB3, which preferentially binds to K63-linked ubiquitin chains 
(Fig 1.3) (Wang et al., 2001; Varfolomeev et al., 2008; Bertrand et al., 2008; Walczak, 
2011). Additionally, the c-IAPs become polyubiquitinated in a K63-dependent manner 
through autoubiquitination, and these ubiquitin chains are thought to recruit the tripartite 
linear ubiquitin chain assembly complex (LUBAC), comprised of Sharpin, HOIL-1, and 
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HOIP (Haas et al., 2009; Gerlach et al., 2011; Walczak, 2011). LUBAC modifies the 
NEMO subunit of the IKK complex with linear ubiquitin chains, which is believed to 
impact its function (Gerlach et al., 2011). IKKβ is phosphorylated by the TAK:TAB 
complex, activating the IKK complex and resulting in the subsequent downstream 
activation of NF-κB (Fig 1.3) (Yang et al., 2001; Takaesu et al., 2003). 
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Figure 1.3 The role of c-IAP1/2 in TNF-R1-mediated NF-κB activation. Upon 
ligand binding to TNR-R1, death domain-containing factors, such as RIP1 and 
TRADD are recruited to the cytoplasmic tail of the receptor. This, in turn, recruits 
additional factors, including TRAF2 and the c-IAPs. The c-IAPs undergo 
autoubiquitination and ubiquitinate RIP1. The ubiquitin chains act as scaffolds to 
recruit LUBAC and the TAB:TAK complex. The IKK complex is modified with a 
linear ubiquitin chain by LUBAC and is activated by phosphorylation by the 
TAB:TAK complex. The IKK complex phosphorylates IκBα, resulting in its 
subsequent proteasome-dependent degradation and the translocation of the canonical 
NF-κB dimer into the nucleus. 
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While the E3 ubiquitin ligase activity of the c-IAPs is involved in the propagation 
of the TNF-R1 signaling cascade, the c-IAPs also play an inhibitory role in regulating 
non-canonical NF-κB in the context of CD30-mediated signaling. Prior to receptor 
activation, the c-IAPs form a complex with TRAF2 and TRAF3. This complex binds 
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Figure 1.4 The role of c-IAP1/2 in CD30-mediated NF-κB activation. Prior to 
stimulation, the c-IAPs form a complex with TRAF2 and TRAF3 and ubiquitinate 
NIK in a K48-dependent manner, resulting in the constitutive degradation of NIK. 
Following receptor activation, the TRAF:c-IAP complex is recruited to the 
cytoplasmic tail of CD30, where the c-IAPs ubiquitinate TRAF3, inducing its 
degradation. TRAF2 and c-IAP1/2 are also degraded, allowing for the accumulation of 
NIK. NIK activates IKKα, which phosphorylates p100. Subsequently, p100 is cleaved, 
allowing the active non-canonical NF-κB dimer to translocate into the nucleus. 
Receptor-mediated canonical NF-κB activation also occurs, albeit through a poorly 
defined mechanism. 
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NIK, which is constitutively expressed (Zarnegar et al., 2008; Vallabhapurapu and Karin, 
2009). Both TRAF2 and TRAF3 have been shown to directly bind NIK (Malinin et al., 
1997; Liao et al., 2004), and the c-IAPs modify NIK with K48-linked ubiquitin chains, 
resulting in its proteasome-dependent degradation (Varfolomeev et al., 2007; Zarnegar et 
al., 2008; Vallabhapurapu et al., 2008; Hacker et al., 2011), thereby repressing non-
canonical NF-κB activation (Fig. 1.4). Following receptor activation, the TRAF:c-IAP 
complex is recruited to the cytoplasmic tail of CD30 via its TRAF-binding domains. 
After this recruitment, the c-IAPs modify TRAF3 with K48-linked ubiquitin chains, 
leading to the degradation of TRAF3 (Fig. 1.4) (Duckett and Thompson, 1997; Zarnegar 
et al., 2008; Vallabhapurapu et al., 2008). TRAF2 and c-IAP1/2 are then subsequently 
degraded following translocation to a detergent insoluble fraction (Duckett and 
Thompson, 1997; Wright et al., 2007; Csomos et al., 2009; Silke and Brink, 2010). The 
absence of the c-IAP:TRAF complex allows NIK levels to accumulate, resulting in the 
activation of non-canonical NF-κB (Fig. 1.4). While the role of c-IAP1/2 in other aspects 
of CD30 signaling remains undefined, CD30-mediated degradation of the c-IAPs is an 
important regulatory event for the activation of non-canonical NF-κB. 
 
Synthetic IAP Antagonism 
Physiological degradation of c-IAP1/2 is dependent on the activation of a limited 
set of receptors, as discussed above. However, over the last decade, a class of small 
molecule compounds has been developed that possess the ability to induce the 
degradation of the IAPs. These compounds are based on the IAP binding motif (IBM) of 
Smac (Schimmer et al., 2004; Li et al., 2004; Sun et al., 2004), and the IBM of Smac is a 
 21 
four residue sequence of Alanine-Valine-Proline-Isoleucine (AVPI) that allows the 
protein to interact with the BIR domains of the IAPs (Liu et al., 2000; Wu et al., 2000). 
Since the caspase:IAP interaction occurs via the BIR domains, binding of Smac interrupts 
this interaction and liberates the caspases for downstream activity. Furthermore, this 
binding of Smac to an IAP can induce the autoubiquitination and degradation of the IAP 
(Csomos et al., 2009). Likewise, the Smac mimetics (SMs), which are also known as IAP 
antagonists, are able to bind the IAPs and induce their degradation (Varfolomeev et al., 
2007; Vince et al., 2007; Darding et al., 2011). Due to the connection between the IAPs 
and cell death, SMs have been actively studied as potential therapeutics against cancer. 
The ability to evade cell death is a characteristic of cancer, and therefore, methods 
to induce cell death in malignant cells have been an active field of study in cancer 
research (Hanahan and Weinberg, 2000). As discussed above, the precise role of the IAPs 
in the progression of cancer is still being studied. However, multiple cancers are 
associated with higher expression of the IAPs, which also correlates with poorer survival 
rates (Xiang et al., 2009; Hussain et al., 2010; Esposito et al., 2007; Krajewska et al., 
2005; Imoto et al., 2002). For these reasons, the IAPs have been considered prime targets 
for therapeutic strategies.  
There are currently two major categories of SMs: monovalent compounds, which 
mimic a single AVPI motif, and bivalent compounds that mimic two AVPI motifs. Both 
classes of SMs have been shown to induce cell death in certain cancers, though bivalent 
compounds are often significantly more potent (Varfolomeev et al., 2007; Vince et al., 
2007; Petersen et al., 2007; Lu et al., 2008). This is thought to be due to their increased 
ability to dimerize the IAPs, inducing their degradation (Varfolomeev et al., 2007; Vince 
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et al., 2007; Lu et al., 2008). Alternatively, the increased potency of bivalent SMs may be 
due to their ability to interact with both BIR2 and BIR3 of XIAP, resulting in more 
efficient caspase activation (Gao et al., 2007; Varfolomeev et al., 2009). There are 
currently a variety of SMs, both monovalent and bivalent, in preclinical and clinical 
development (Fulda and Vucic, 2012).  
While the ability of SMs to liberate caspases from XIAP may contribute to the 
observed induction of cell death, this is now believed to represent only one aspect of their 
mechanism. SMs have been shown to preferentially target and degrade the c-IAPs over 
XIAP (Varfolomeev et al., 2007; Lu et al., 2008), and while this does not preclude the 
inhibition of XIAP, it suggested a more prominent role for the c-IAPs in regulating SM-
induced cell death. It is currently thought that SM-induced killing is dependent on TNF 
(Varfolomeev et al., 2007; Vince et al., 2007). More specifically, following SM 
treatment, the c-IAPs are degraded, and TNF is produced in an autocrine or paracrine 
manner, activating TNF-R1. However, in the absence of c-IAP1/2, the ubiquitin scaffolds 
that help form the receptor signaling complex cannot be properly formed, leading RIP1 to 
then associate with TRADD, FADD, and caspase-8 to form a death inducing signaling 
complex, resulting in caspase activation and cell death (Fig. 1.5) (Varfolomeev et al., 
2008). Currently, cells can be divided into two major categories: those that are killed by 
SM treatment alone, and cells that are not killed by SM treatment alone but are sensitized 
to exogenous TNF (Petersen et al., 2007; Tenev et al., 2011). Cells in the former category 
are able to produce autocrine TNF through a NF-κB-dependent manner (Petersen et al., 
2007), while cells in the latter category, conversely, do not produce TNF following SM 
treatment, and therefore require an additional source of TNF (Vince et al., 2007). More 
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recently, another mechanism of cell death has been proposed which involves the 
formation of the ripoptosome following SM treatment (Fig. 1.5). The mechanism of the 
complex has been described above, but importantly, ripoptosome-mediated cell death is 
independent of TNF and the mitochondrial death pathways (Tenev et al., 2011; 
Feoktistova et al., 2011), indicating that SM-induced death may not always be reliant on 
TNF. 
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Figure 1.5 Current model of Smac mimetic-induced cell death. Smac mimetic 
treatment results in the degradation of c-IAP1/2. In certain cells, this leads to the NF-
κB-dependent production of autocrine TNF. In the absence of c-IAP1/2, normal TNF-
R1 signaling is impaired, resulting in the formation of a death inducing signaling 
complex called Complex IIB. This complex then activates downstream caspases and 
cell death. More recently, another mechanism of SM-induced cell death has been 
described. Degradation of c-IAP1/2 results in the receptor-independent formation of a 
complex called the Ripoptosome. This complex can induce apoptosis or necroptosis, 
depending on the status of caspase-8 activation and the presence of RIP3.  
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While the targeting of the IAPs may be a promising therapeutic strategy for 
certain cancers, in other malignancies, the absence of properly functioning IAPs appears 
to contribute to the disease. Deletions of c-IAP1 and c-IAP2 were found in multiple 
myeloma and resulted in constitutive activation of non-canonical NF-κB, potentially 
contributing to disease progression (Keats et al., 2007; Annunziata et al., 2007). 
Additionally, a t(11;18)(q21;q21) chromosomal translocation frequently occurs in 
mucosa-associated lymphoid tissue (MALT) lymphoma, resulting in a fused protein of 
the BIR domains of c-IAP2 and the paracaspase function of MALT translocation protein 
1 (MALT1), leading to constitutive activation of both canonical and non-canonical NF-
κB (Dierlamm et al., 1999; Rosebeck et al., 2011; Rosebeck et al., 2014). These data 
suggest that the IAPs have multifaceted, and perhaps contradictory, functions in cancer, 
and therefore, targeting the IAPs may be a successful strategy in certain cases, but may 
exacerbate the disease in other situations. SM-induced degradation of c-IAP1/2 would 
allow NIK to accumulate, leading to the constitutive activation of non-canonical NF-κB 
and potentially contributing to disease progression and initiation of cytokine release 
syndrome, which has been observed in early clinical trials with SMs (Infante et al., 2014). 
Therefore, the consequences of IAP antagonism warrant additional study.  
CD30 activation and SM treatment represent physiological and synthetic means, 
respectively, to induce the degradation of c-IAP1/2 and therefore represent useful tools 
for investigating the consequences of c-IAP1/2 activity. While both stimuli result in c-
IAP degradation, it is not clear if the downstream effects of this event are similar. 
Likewise, it is known that both stimuli activate NF-κB, but the full extent of how the 
 25 
cellular context impacts the activity of c-IAP1/2 and its regulation of intracellular 
signaling is not fully understood.  
 
Dissertation Objectives 
The goal of this dissertation was to further explore the role of ubiquitin in 
signaling and specifically investigate the multifaceted roles and outcomes of c-IAP1/2 
activity in key intracellular signaling pathways. Their role in regulating NF-κB was 
initially examined by comparing the effects of physiological and synthetic IAP 
antagonism by receptor activation and Smac mimetic treatment, respectively. The NF-κB 
signaling pathways regulated by c-IAP1/2 were then further investigated, characterizing 
the role of these pathways in different cellular contexts. This dissertation has been 
organized into the following specific aims: 
Specific Aim 1 (Chapter II): Compare physiological and synthetic IAP 
antagonism and investigate and compare the downstream consequences following 
each stimulus. 
Specific Aim 2 (Chapter III): Investigate the cell type-specificity of the 
downstream effects of IAP antagonism, asking how the cellular context 
contributes to the efficacy of SM function.  
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 CHAPTER II
Effects of Physiological and Synthetic IAP Antagonism on c-IAP-dependent 
Signaling 
 
Summary 
The ubiquitin ligases c-IAP1/2 play central roles in signal transduction mediated 
by numerous receptors that participate in inflammatory and immune responses. Their 
degradation is concomitant with the activation of certain pathways and is physiologically 
induced by activation of receptors. A number of synthetic compounds have been 
developed that also target the c-IAPs and induce their degradation. However, the extent 
of a synthetic IAP antagonist’s ability to mirror the transcriptional program by a 
physiological signal remains unclear. A systems approach was used to compare the 
transcriptional programs triggered by activation of CD30, a receptor previously shown to 
degrade the c-IAPs, to SM-164, a synthetic IAP antagonist that specifically triggers c-
IAP degradation. Employing a technique that allows for the specific analysis of newly 
transcribed RNA, comparative transcriptome profiles for CD30 activation and SM-164 
treatment were generated, revealing novel functions of IAP antagonists and consequences 
of c-IAP1/2 degradation that included a role for c-IAP1/2 in the regulation of the 
ribosome and protein synthesis. These findings expand our knowledge of the roles of c-
IAP1/2 in signaling and provide insight into the mechanism of synthetic IAP antagonists, 
furthering our understanding of their therapeutic potential. 
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Introduction 
As discussed in Chapter I, the IAP proteins are central mediators of a divergent 
group of cellular signaling pathways, largely involved in immune and inflammatory 
responses (Salvesen and Duckett, 2002). Two of these proteins, c-IAP1/2, have been 
implicated as key regulators of NF-κB, a protein family comprised of five different 
members that dimerize to form active transcription factors (Hayden and Ghosh, 2008; 
Smale, 2012). The best-characterized NF-κB dimers are p65:p50 and RelB:p52, which 
are often referred to as canonical and non-canonical NF-κB, respectively 
(Vallabhapurapu and Karin, 2009).  
 The canonical and non-canonical NF-κB pathways are activated by members of 
the tumor necrosis factor (TNF) receptor superfamily and play important roles in the 
immune response, inflammation, and cancer (DiDonato et al., 2012; Perkins, 2012). 
While c-IAP1/2 have a demonstrated role in the activation of canonical NF-κB following 
TNF treatment, their degradation is required to activate the non-canonical NF-κB 
pathway, a signaling cascade that physiologically occurs following activation of a limited 
subset of the TNF receptor superfamily that exhibit direct binding to TRAF adaptor 
proteins, including CD30, CD40, and TNF-R2 (Hacker et al., 2011; Wright et al., 2007; 
Wright and Duckett, 2009). Prior to stimulation, c-IAP1/2 form a complex with TRAF2 
and TRAF3, and this complex is thought to bind and degrade the constitutively expressed 
NIK (Vallabhapurapu et al., 2008). Following ligand binding, the receptor recruits the 
TRAF:c-IAP1/2 complex through the direct binding of the TRAFs. This interaction 
subsequently triggers the degradation of c-IAP1/2 and results in the gradual accumulation 
of NIK. This, in turn, begins a signaling cascade that leads to the phosphorylation and 
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processing of the NF-κB precursor p100 to the active NF-κB subunit p52. The p52 
moiety can dimerize with RelB to form the non-canonical NF-κB transcription factor that 
subsequently regulates an incompletely defined list of genes involved in multiple cellular 
processes, including the immune response (Smale, 2012; Vallabhapurapu et al., 2008; 
Vallabhapurapu and Karin, 2009; Csomos et al., 2009). 
As described in Chapter I, the degradation of c-IAP1/2 can be recreated 
experimentally using a class of synthetic, small molecule compounds known as Smac 
mimetics (SMs) or IAP antagonists (Varfolomeev et al., 2007; Vince et al., 2007; Lu et 
al., 2008). These compounds are structurally based on the IAP binding motif (IBM) of a 
physiological binding partner of the IAPs known as second mitochondria-derived 
activator of caspase/direct inhibitor of apoptosis-binding protein with low isoelectric 
point (Smac/DIABLO). These compounds bind to c-IAP1/2 and trigger their 
autoubiquitination and subsequent degradation, resulting in the processing of p100 to p52 
and the activation of non-canonical NF-κB (Csomos et al., 2009; Varfolomeev et al., 
2007; Vince et al., 2007; Lu et al., 2008; Darding et al., 2011). Additionally, SM 
treatment has been shown to activate canonical NF-κB under some circumstances, though 
the exact mechanism remains undefined (Varfolomeev et al., 2007; Vince et al., 2007). 
While SMs have been shown to replicate aspects of receptor activation, the extent of the 
functional overlap between the two classes of stimuli remains unclear.  
 In this chapter, a systems approach was used to extensively compare the 
downstream effects of physiological and synthetic IAP antagonism. This was done in a 
cellular system in which both receptor activation and SM treatment lead to the 
degradation of c-IAP1/2 and result in canonical and non-canonical NF-κB activation. 
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While stimulation of the receptor also induced additional signaling pathways, such as 
JNK and ERK, SM treatment did not, demonstrating that these pathways were 
independent of c-IAP1/2. To characterize the transcriptional consequences of IAP 
antagonism-induced NF-κB activation, Bru-seq, a recently developed technique that 
specifically analyzes newly transcribed RNA, was used to identify gene expression 
profiles following each stimulus. While overlapping, the resulting transcriptome profiles 
revealed differences between the two modes of IAP antagonism, suggesting that 
consequences of c-IAP degradatiom may be context-dependent. Furthermore, analysis of 
the transcriptome data revealed novel functions of c-IAP1/2 degradation and sequelae of 
SM treatment. One novel consequence of c-IAP1/2 degradation was the decreased 
expression of genes related to the ribosome and translation. In support of this finding, 
biological assays found that SM treatment resulted in decreased protein synthesis. These 
findings identify novel functions for the c-IAPs, and provide insight into the mechanism 
of SMs and their therapeutic potential. 
 
Results 
Smac mimetic treatment models CD30-mediated c-IAP1/2 degradation and NF-κB 
activation 
To evaluate the consequences of c-IAP degradation, the effects of a Smac 
mimetic were compared to those of a cell surface receptor previously shown to induce the 
degradation of the c-IAPs upon activation. As discussed in Chapter I, CD30 is a member 
of the TNF receptor superfamily that binds and degrades c-IAP1/2 as part of a larger 
complex. CD30 is highly expressed on the surface of certain lymphoma and leukemia 
cells, including anaplastic large cell lymphoma (ALCL) and Hodgkin’s lymphoma cells 
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(Chiarle et al., 1999; Mir et al., 2000). In healthy individuals, CD30 expression is 
restricted to a small subset of activated T and B cells, and while its physiological role 
remains poorly defined, the ability of the receptor to degrade c-IAP1/2 following 
activation has been previously documented (Csomos et al., 2009). Using a cell-based 
system for CD30 stimulation (Wright et al., 2007) and the ALCL cell lines Karpas 299 
and Michel (Tian et al., 1995), the consequences of Smac mimetic (SM) treatment and 
CD30 activation were compared. Both stimuli resulted in the degradation of c-IAP1 and 
c-IAP2 (Fig. 2.1A, 2.2A) and induced the processing of p100 to p52, a widely used 
marker of non-canonical NF-κB activation (Fig. 2.1B, 2.2A). Both CD30 stimulation and 
SM treatment resulted in nuclear translocation of DNA-binding canonical and non-
canonical NF-κB, as detected by electrophoretic mobility shift assay (EMSA) and 
confirmed by supershift analysis (Fig. 2.1C), indicating that SM treatment models CD30-
mediated NF-κB activation. While SM treatment has previously been shown to induce 
autocrine TNF production (Varfolomeev et al., 2007; Vince et al., 2007), pretreatment 
with the TNF inhibitor Enbrel did not prevent the NF-κB activation (Fig. 2.1D), 
indicating that SM-induced NF-κB was independent of TNF. In addition to NF-κB 
activation, members of the TNFR superfamily can trigger other signaling cascades, 
including the JNK and ERK pathways (Silke, 2011). To test if SM treatment and CD30 
stimulation activated these pathways, Karpas 299 and Michel cells were briefly treated 
with SM or stimulated with CD30L, and phosphorylation of JNK and ERK was assessed. 
While receptor stimulation activated these pathways, SM treatment did not (Fig. 2.1E). 
Additionally, inhibition of JNK and ERK did not affect NF-κB activation, indicating that 
this occurred independently of CD30-mediated JNK and ERK signaling (Fig. 2.1F). 
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Collectively, these results demonstrate that the ability of SM treatment to model receptor 
signaling is limited to activation of NF-κB.  
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Figure 2.1 Smac mimetic treatment models CD30-mediated NF-κB activation 
A. Karpas 299 cells were treated with 100 nM SM-164 or exposed to CHO cells 
expressing CD30L for 3 h. Control samples were treated with DMSO or exposed to 
control CHO cells. Whole cell lysates were prepared, and c-IAP1/2 degradation was 
assessed by Western blot. B. Karpas 299 cells were stimulated as in A. Whole cell 
lysates were prepared, and p100 processing was analyzed by Western blot. Bands 
marked with an asterisk (*) are non-specific. C. Karpas 299 cells were treated as in A, 
nuclear extracts were collected, and NF-κB activation was analyzed by EMSA. To 
identify the NF-κB bands, the CD30L and SM-164 treated samples were incubated 
with antibodies against the indicated NF-κB subunits or GST as a control and used in 
a supershift assay. D. Karpas 299 cells were pretreated with the TNF inhibitor Enbrel 
at 10 µg/mL for 1 h. The cells were then treated with 100 nM SM-164 for 3 h or 500 
U/mL TNF for 30 min. Nuclear extracts were isolated, and NF-κB activation was 
analyzed by EMSA. E. Karpas 299 and Michel cells were incubated with CHO cells 
expressing CD30L or treated with 100 nM SM-164 for 15 min. Whole cell lysates 
were collected and the activation status of the indicated MAP kinase pathways was 
determined by Western blot. F. Karpas 299 cells were pretreated with 25 µM of the 
JNK inhibitor SP600125 and 50 nM of the MEK inhibitor Trametinib for 1h. The cells 
were then exposed to CD30L for the indicated times. Following treatment, nuclear 
extracts and whole cell lysates were collected from the samples. The nuclear extracts 
were used to assess NF-κB activation by EMSA. Can. NF-κB, canonical NF-κB; Non-
can. NF-κB, non-canonical NF-κB; N.S., non-specific. 
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Kinetics of NF-κB induction by receptor activation and SM treatment 
As described above, both CD30 activation and SM treatment were found to 
trigger the degradation of c-IAP1/2 and to activate canonical and non-canonical NF-κB. 
However, it was unclear if these processes occurred with similar kinetics. Time course 
experiments were performed with each stimulus to examine this question. Degradation of 
c-IAP1/2 occurred rapidly following CD30 stimulation and SM treatment, and substantial 
loss of protein was observed within 15 min of treatment in both ALCL cell lines (Fig. 
2.2A). Additionally, both stimuli resulted in p100 processing to the active non-canonical 
NF-κB subunit p52 at 3 h (Fig. 2.2A), consistent with previous reports describing the 
delayed kinetics of non-canonical NF-κB activation (Vallabhapurapu et al., 2008). 
Notably, CD30 consistently appeared to be a stronger inducer of NF-κB than SM 
treatment (Fig. 2.2), and this observation may be due to the presence of less nuclear NF-
κB or weaker DNA-binding activity of NF-κB following SM treatment. A non-canonical 
NF-κB nuclear protein complex was detected at 3 h by EMSA (Fig. 2.2B-D), indicating 
that CD30 stimulation and SM treatment activate non-canonical NF-κB with similar 
kinetics. Activation of canonical NF-κB, however, differed between the two stimuli. 
CD30-mediated canonical NF-κB occurred rapidly, being observed 15-30 min following 
receptor activation, and remained observable throughout the entire time course (Fig. 
2.2B, D). Conversely, SM-induced canonical NF-κB was delayed and initially observed 
at 1 h (Fig. 2.2C, D), and the level of active canonical NF-κB triggered by SM peaked 
around 6 h before decreasing throughout the remaining time points. This decrease in 
canonical NF-κB coincided with activation of non-canonical NF-κB (Fig. 2.2C, D). 
Taken together, these data indicated that CD30 activation and SM treatment induced c-
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IAP1/2 degradation and activated the same NF-κB pathways, albeit with differing rates, 
suggesting potential mechanistic and functional differences. 
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Comparison of gene regulation induced by physiological and synthetic IAP 
antagonism 
While the ability of SMs to activate NF-κB has been previously reported 
(Varfolomeev et al., 2007; Vince et al., 2007), it is not known if this resulted in the 
regulation of a similar gene expression profile as receptor signaling. To address this 
question, a recently developed technique, Bru-seq, that allows for transcriptome analysis 
of newly transcribed RNA was employed (Paulsen et al., 2013; Paulsen et al., 2014). As 
depicted schematically in Figure 2.3A, Karpas 299 cells were treated with SM or exposed 
to CD30L, incubated with bromouridine, and the bromouridine-labeled RNA was isolated 
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Figure 2.2 Kinetics of NF-κB induction by receptor activation and SM treatment. 
A. Karpas 299 and Michel cells were exposed to CD30L-expressing CHO cells or 
control CHO cells (A) or treated with 100 nM SM-164 or DMSO (B) for the indicated 
times. Whole cell lysates were collected and used to assess p100 processing and c-
IAP1/2 degradation by Western blot. Bands marked with an asterisk (*) are non-
specific. B-D. Karpas 299 (B, C) or Michel (D) cells were exposed to CD30L or 
incubated with 100 nM SM-164 for the indicated times. Nuclear extracts were 
prepared and NF-κB activation was measured by EMSA. 
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and converted into cDNA libraries for deep sequencing. In the initial analysis of the Bru-
seq data, we compared the expression of two well-characterized NF-κB gene targets: 
BIRC3, which encodes the c-IAP2 protein, and NFKBIA, the gene encoding IκBα 
(Csomos et al., 2009; Paulsen et al., 2013; Kenneth et al., 2014). The profiles of the 
mapped sequencing reads were similar for both stimuli (Fig. 2.3B, C), indicating that the 
stimuli produced similarly processed transcripts. Transcription of both genes was induced 
upon each treatment, with BIRC3 being the most highly transcribed gene in both cases. 
Compared to an unstimulated sample, transcription of BIRC3 was induced 12-fold 
following CD30 activation, while SM treatment resulted in a 7-fold increase in BIRC3 
transcription (Fig. 2.3B). The Bru-seq results were mirrored by qRT-PCR experiments 
that also illustrated a more robust expression of genes following CD30 stimulation. 
Similar to BIRC3, expression of NFKBIA was also markedly higher following CD30L 
than SM (12-fold increase and 7-fold increase, respectively) (Fig. 2.3C). Since both 
stimuli degraded c-IAP1/2 to the same degree (Fig. 2.1A) and with similar rates (Fig. 
2.2A, B), these results indicate that the receptor may provide additional signals that 
strengthen the magnitude of NF-κB activation. Notably, IL8, the gene encoding the 
interleukin-8 cytokine and a canonical NF-κB gene target (Paulsen et al., 2013), 
exhibited the second highest expression following CD30 stimulation (12-fold increase), 
but was not significantly affected by SM treatment (Fig. 2.3D), indicating different 
functional consequences of NF-κB activation by the two stimuli. Karpas 299 cells 
exposed to the control CHO cells exhibited a somewhat different pattern of basal gene 
expression compared to the cells treated with DMSO. However, this technical aspect did 
not appear to significantly affect the observed stimulus-induced gene expression profiles. 
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To better visualize and compare the stimuli-induced transcriptomes, the change in 
transcription of genes following SM treatment was plotted against the change in 
transcription of genes following CD30 activation (Fig. 2.3E). While certain genes were 
affected by both stimuli, such as BIRC3 and NFKBIA, the transcription of other genes, 
like IL8, were modified by only one of the stimuli. Collectively, these data demonstrate 
that the transcriptional consequences of IAP antagonism by SM reflect aspects of 
receptor-induced signaling, while also providing evidence of functional differences 
between the two forms of IAP antagonism. 
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Gene set analysis reveals novel roles for c-IAP1/2 and IAP antagonists 
The initial analysis of the transcriptome profiles generated by each stimulus 
highlighted the variety of genes regulated by c-IAP1/2 degradation. Due to the initial 
complexity of classifying these genes with their wide functional diversity, gene set 
enrichment analysis (GSEA) was performed, allowing for the identification of groups of 
genes that exhibit similar changes in expression using gene sets that have been 
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Figure 2.3 Comparison of gene regulation induced by physiological and synthetic 
IAP antagonism. 
A. Diagram of the Bru-seq procedure. Karpas 299 cells were exposed to CD30L or 
treated with 100 nM SM-164 for the indicated times. B-D. Sequencing reads from 
nascent RNA expressed as reads per thousand base pairs per 1 million reads (RPKM) 
and mapped to the BIRC3 gene (B), NFKBIA gene (C), and IL8 gene (D) with 
reference sequence annotation below. The exons and UTRs are denoted as black lines. 
The CD30L and SM-164 treated samples are shown in blue, and the unstimulated 
control samples are shown in yellow. For the qRT-PCR, Karpas 299 cells were 
exposed to CD30L or treated with 100 nM SM-164 for the indicated times. RNA was 
isolated and converted to cDNA, and the expression of the indicated genes was 
measured. E. The log2 fold change of genes from the SM-164 treated Bru-seq sample 
were plotted against the log2 fold change of genes from the CD30L Bru-seq sample. 
The location of BIRC3, NFKBIA, and IL8 are in blue, and the red dots represent the 
genes in the KEGG_RIBOSOME gene set. These experiments were performed with 
the help of Dr. Mats Ljungman and his lab. 
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categorized based on shared, biologically relevant characteristics, such as belonging to a 
common enzymatic pathway or presence in the same cellular compartment (Subramanian 
et al., 2005). GSEA has advantages over traditional strategies of gene expression 
analysis, including the ability to detect biologically significant processes involving 
groups of genes that show only modest changes in expression (Subramanian et al., 2005). 
Analysis of the GSEA data indicated that CD30 activation and SM treatment collectively 
modulated 256 gene sets (Fig. 2.4A). There were 119 CD30-specific gene sets identified 
(Fig. 2.4A), and it was expected that CD30-specific gene sets would be identified since 
the receptor activated multiple pathways that were not activated by SM (Fig. 2.1). 
Examples of CD30-specific gene sets are shown in Figure 2.4B. Additionally, 62 SM-
specific gene sets were identified (Fig. 2.4A) even though SM treatment was thought to 
mimic receptor signaling by degrading c-IAP1/2, suggesting that the SM may have 
additional, uncharacterized effects. These effects may be regulated by additional IAPs, 
such as X-linked inhibitor of apoptosis (XIAP), which can be antagonized by SMs 
(Varfolomeev et al., 2007; Vince et al., 2007; Lu et al., 2008). Notably, the majority of 
the SM-specific gene sets were down-regulated by the compound and several gene sets 
were functionally related to metabolism and protein synthesis (Fig. 2.4C).  
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Figure 2.4 Gene set analysis reveals novel roles for c-IAP1/2 and IAP antagonists. 
A. A summary of the results from gene set enrichment analysis (GSEA) performed 
with the Bru-seq data. The numbers are gene sets modulated by the designated 
stimulus. The number of gene sets up and down-regulated are noted. B-D. Examples 
of gene sets with false discovery rates (FDR) < 0.05 that are regulated by CD30 alone 
(B), SM treatment alone (C), or regulated by both stimuli (D). The bars represent 
normalized enrichment score for the gene set. These experiments were performed with 
the help of Dr. Mats Ljungman and his lab. 
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The GSEA data identified 75 gene sets shared between CD30 activation and SM 
treatment (Fig. 2.4A). Many of these gene sets were expected, as they were related to 
functions shared between the two stimuli, such as regulation of NF-κB or involvement in 
TNF-R2 and cell death signaling cascades (Fig. 2.4D). Conversely, it was unexpected 
that there would be gene sets significantly down-regulated by both stimuli. Functionally, 
many of these gene sets were involved the regulation of the ribosome and translation, 
with SM treatment resulting in a more substantial down-regulation of the transcription of 
these genes and gene sets (Fig. 2.3E, 2.4D). Experiments with a different Smac mimetic, 
Birinapant, did not affect the expression of ribosomal genes to the extent of SM-164 (Fig. 
2.5A). However, Birinapant was a weaker inducer of c-IAP2 degradation and NF-κB 
activation (Fig. 2.5B), suggesting that the effect on ribosomal gene expression is 
dependent on efficient degradation of both c-IAP1 and c-IAP2, as well as the subsequent 
activation of NF-κB. Additionally, treatment with the caspase inhibitor z-VAD-fmk 
abrogated the SM-induced down-regulation of ribosomal genes (Fig. 2.6), indicating a 
potential regulatory role for caspases in this process. While further work is needed to 
elucidate the exact mechanism, these analyses indicate that IAP antagonism by receptor 
activation or treatment with a synthetic compound has diverse functional consequences, 
including newly identified potential roles in the regulation of ribosome biogenesis and 
protein synthesis.  
 
 54 
 
 
 
 
 
0
0.3
0.6
0.9
1.2
- SM-164 Birinapant
RPS15
Fo
ld
 C
ha
ng
e
0
0.275
0.550
0.825
1.100
- SM-164 Birinapant
RPS19
Fo
ld
 C
ha
ng
e
0
0.275
0.550
0.825
1.100
- SM-164 Birinapant
RPL28
Fo
ld
 C
ha
ng
e
0
0.3
0.6
0.9
1.2
- SM-164 Birinapant
RPL35
Fo
ld
 C
ha
ng
e
0
0.275
0.550
0.825
1.100
- SM-164 Birinapant
FAU
Fo
ld
 C
ha
ng
e
A.
SM
-16
4
Bir
ina
pa
nt
-
N.S.
N.S.
Can.
Non-can. 
B.
Actin
c-IAP2
c-IAP1
Figure 2.5 Birinapant is a weak inducer of c-IAP2 degradation, NF-κB 
activation, and down-regulation of ribosomal gene expression. 
A. Karpas 299 cells were treated with 100 nM Birinapant or 100 nM SM-164 for 6 h. 
RNA was then isolated and converted to cDNA. The expression of the indicated 
ribosomal genes was measured by qRT-PCR. B. Karpas 299 cells were treated with 
100 nM SM-164 or 100 nM Birinapant for 3 h. Nuclear extracts and whole cell lysates 
were then prepared from the samples. The nuclear extracts were used to assess NF-κB 
activation by EMSA, and the whole cell lysates were used to assess c-IAP 
degradation. Can. NF-κB, canonical NF-κB; Non-can. NF-κB, non-canonical NF-κB; 
N.S., non-specific. 
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IAP antagonism results in decreased protein synthesis 
As described above, the GSEA results indicated novel roles for c-IAP1/2 in the 
regulation of genes related to the ribosome and translation. To test if the observed 
transcriptome results had a cellular consequence, protein synthesis was measured 
following CD30 activation and SM treatment using an assay based on incorporation of a 
methionine analogue (Signer et al., 2014; Zhang et al., 2014). Karpas 299 cells were 
treated with the designated stimulus and then incubated in L-methionine-free medium that 
had been supplemented with L-methionine or the methionine analogue L-
homopropargylglycine (HPG). The incorporation of HPG was then assessed by flow 
cytometry. SM treatment resulted in a measurable decrease in protein synthesis by 3 h, 
and this decrease continued with longer treatment times (Fig. 2.7A-C). Importantly, 
0
0.3
0.6
0.9
1.2
- SM-164
RPS15
F
o
ld
 C
ha
ng
e
Control
z-VAD-fmk
0
0.325
0.650
0.975
1.300
- SM-164
RPS19
F
o
ld
 C
ha
ng
e
Control
z-VAD-fmk
0
0.275
0.550
0.825
1.100
- SM-164
RPL28
F
o
ld
 C
ha
ng
e
Control
z-VAD-fmk
0
0.275
0.550
0.825
1.100
- SM-164
RPL35
F
o
ld
 C
ha
ng
e
Control
z-VAD-fmk
0
0.3
0.6
0.9
1.2
- SM-164
FAU
F
o
ld
 C
ha
ng
e
Control
z-VAD-fmk
Figure 2.6. Caspase inhibition prevents down-regulation of ribosomal gene 
expression. 
Karpas 299 cells were pretreated with 10 µM z-VAD-fmk for 1 h. The cells were then 
treated with 100 nM SM-164 for 6 h. RNA was then harvested and converted to 
cDNA. The expression of the indicated ribosomal genes was measured by qRT-PCR. 
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Figure 2.7 IAP antagonism results in decreased protein synthesis. 
A-C. Karpas 299 cells were incubated with 100 nM SM-164 or 100 µg/mL 
cycloheximide (CHX) for the indicated times. The medium was then replaced with 
methionine-free medium supplemented with methionine or the methionine analogue 
HPG, and the cells were incubated for 1 h. HPG incorporation was measured by flow 
cytometry. D-F. Karpas 299 cells were exposed to CD30L or 100 µg/mL CHX for the 
indicated times. The medium was then replaced with methionine-free medium 
supplemented with methionine or HPG, and the cells were incubated for 1 h. HPG 
incorporation was measured by flow cytometry. Data represent the mean ± standard 
deviation of at least three independent experiments (*P < 0.01). 
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the decrease in protein synthesis was initially observed prior to any substantial SM-
induced cell death (Fig. 2.8). In contrast, CD30 activation had a minor effect on protein 
synthesis at early time points and only had a substantial effect by 24 h (Fig. 2.7D-F), and 
similar results were also observed in Michel cells (Kocab et al., 2015). These findings 
indicate that IAP antagonism, in the system tested, has an inhibitory impact on global 
protein synthesis, revealing a novel regulatory consequence for c-IAP1/2 degradation and 
SM treatment.  
 
Discussion 
In this chapter, the consequences of IAP antagonism on gene regulation by 
physiological and synthetic stimuli were examined, and genes and pathways unique to 
each stimulus were identified, as were novel processes affected by both inducers of c-
IAP1/2 degradation. One finding of particular interest was the down-regulation of genes 
related to the ribosome and translation. This observation was identified following SM 
treatment and CD30 activation, and resulted in decreased protein synthesis following 
both stimuli, though treatment with the Smac mimetic had an earlier observable effect on 
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Figure 2.8 Viability following Smac mimetic treatment. 
Karpas 299 cells were treated with 100 nM SM-164 for the indicated times, and cell 
viability was measured by propidium iodide exclusion and flow cytometry. 
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protein synthesis than CD30 stimulation, which only became apparent at 24 h (Fig. 2.7). 
It has been previously established that SMs induce death in certain cells, and that this 
killing is dependent on TNF (Varfolomeev et al., 2007; Vince et al., 2007). However, this 
study provides evidence suggesting an additional mechanism of SM killing. In this 
model, SM triggers the degradation of c-IAP1/2 and results in the shutdown of protein 
synthesis, partially mimicking the effects of cycloheximide. The lethality of TNF would 
then be due, at least in part, to the inability to synthesize pro-survival proteins, similar to 
established mechanisms of TNF killing (Vandenabeele et al., 2010; Darding and Meier, 
2012; Oeckinghaus et al., 2011).  
The consequences of CD30-mediated degradation of c-IAP1/2 differed from the 
IAP antagonism induced by SM treatment, as CD30 activation did not exert as rapid of an 
effect on protein synthesis as compared to SM treatment. Furthermore, the decrease in 
protein synthesis was observed at 24 h, which coincided with previous reports of CD30-
mediated cell cycle arrest at that time point (Wright et al., 2007; Buchan and Al-
Shamkhani, 2012a). Since there is an established connection between cell cycle arrest and 
decreased protein synthesis (Ruggero and Pandolfi, 2003), this observation raises the 
intriguing possibility that c-IAP1/2 may regulate cell cycle arrest through their control of 
protein synthesis.  
As noted above, CD30 and SM affected protein synthesis at different rates, and 
this may be due to several reasons, such as variable expression of CD30 on the cells, 
additional pathways activated by receptor stimulation such as MAPK pathways (Fig. 2.1), 
unique genes regulated by the receptor (Fig. 2.3, 2.4), or a combination thereof. 
Similarly, the unique consequences of SM treatment may contribute to the observed 
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differences. One potentially important difference may be the mechanism of canonical 
NF-κB activation by CD30, which appears to differ from SM-induced canonical NF-κB. 
CD30, like its close TNFR superfamily relatives, is thought to activate NF-κB through its 
TRAF binding domains (Buchan and Al-Shamkhani, 2012a; Matsuzawa et al., 2008; 
Duckett et al., 1997). However, it has also been shown that CD30 can activate NF-κB in 
the absence of its TRAF binding domains (Buchan and Al-Shamkhani, 2012b; Duckett et 
al., 1997), suggesting that CD30 may activate multiple NF-κB pathways with undefined 
functions. Less is known, however, about SM-induced canonical NF-κB. Since SM-
induced canonical NF-κB appears to be due to c-IAP1/2 degradation, it may be reliant on 
the accumulation of NIK, a protein normally associated with non-canonical NF-κB 
activation but that also has a reported ability to activate canonical NF-κB (Malinin et al., 
1997; Zarnegar et al., 2008). The potential mechanistic difference in canonical NF-κB 
activation is supported by the delayed kinetics of NF-κB activation after SM treatment 
(Fig. 2.2), possibly suggesting a reliance on the accumulation of NIK. Furthermore, SM 
treatment resulted in a weaker NF-κB signal (Fig. 2.2), potentially indicating additional 
mechanistic divergence from receptor signaling. Moreover, the canonical NF-κB 
activated by CD30 may be functionally distinct from the NF-κB activated by SM, 
potentially explaining the unique gene regulation by each stimulus.  
In addition to differences in downstream gene targets, the mechanisms of 
receptor-induced and pharmacological IAP antagonism are intrinsically different. 
Receptor-mediated c-IAP1/2 degradation occurs in parallel with TRAF2 degradation 
(Csomos et al., 2009; Duckett and Thompson, 1997) and is dependent on translocation of 
the c-IAP:TRAF2 complex to an insoluble cellular fraction (Wright et al., 2007). In 
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contrast, SMs directly bind to c-IAP1/2 and selectively trigger their autoubiquitination 
and subsequent degradation without degrading TRAF2 (Darding et al., 2011; Sun et al., 
2007; Csomos et al., 2009). This highlights another facet of SMs not shared with receptor 
signaling that may have downstream consequences, as it has been reported that TRAF2 
overexpression can trigger p100 processing (Csomos et al., 2009). Furthermore, SMs 
have been shown to inhibit XIAP, and while SM-induced degradation of XIAP is not 
always observed (Lu et al., 2008), the SM may still bind and inhibit XIAP, a component 
in multiple signaling pathways (Galban and Duckett, 2010; Kenneth and Duckett, 2012), 
potentially resulting in cellular consequences distinct from CD30 activation, which is not 
thought to affect XIAP. Notably, caspase inhibition appeared to negate SM-induced 
ribosomal gene regulation (Fig. 2.6), potentially supporting a role for XIAP and its 
caspase-binding activity. In addition to providing insight into the functions of c-IAP1/2 in 
signaling, these findings highlight unique aspects of Smac mimetics that should be useful 
for defining their therapeutic value, including their regulation of protein synthesis. 
 
Materials and Methods 
Cell lines and culture conditions. Karpas 299 and Michel cells were grown in RPMI 
1640 (Mediatech, Herndon, VA, USA) medium supplemented with 10% FBS and 2 mM 
L-glutamine. The generation of the CD30L+ Chinese hamster ovary (CHO) cells has been 
previously described (Wright et al., 2007). CHO cells and CD30L+ CHO cells were 
cultured in F-12 nutrient medium (Gibco, Carlsbad, CA, USA) supplemented with 10% 
FBS and 2 mL L-glutamine. All cells were maintained at 37°C in an atmosphere of 5% 
CO2. 
 61 
 
Materials. The following primary antibodies were used in this study: anti-p100/p52 
(Millipore); anti-c-IAP1 (Enzo Life Sciences, Farmingdale, NY, USA); anti-c-IAP2 (Cell 
Signaling, Danvers, MA, USA); anti-GST, anti-p65, and anti-RelB (Santa Cruz 
Biotechnology, San Diego, CA, USA); anti-phospho-JNK, anti-JNK, anti-phospho-ERK, 
and anti-ERK (Cell Signaling); and anti-β-actin (Sigma-Aldrich, St. Louis, MO, USA). 
The Smac mimetic SM-164 (Sun et al., 2007) was a kind gift from Dr. Shaomeng Wang 
(University of Michigan). Materials used in this study were: Birinapant (ChemieTek, 
Indianapolis, IN, USA), Enbrel (University of Michigan Hospital pharmacy), z-vad-fmk 
(Cayman Chemical, Ann Arbor, MI, USA), Trametinib (LC Laboratories, Woburn, MA, 
USA) and SP600125 (SelleckChem, Houston, TX, USA).  
 
CD30 stimulation. As described previously (Wright et al., 2007), Karpas 299 cells were 
exposed for the times indicated to either CHO cells (negative control) or CD30L+ CHO 
cells which had been seeded in 10 cm plates. Following the CD30 stimulation, the Karpas 
299 cells were collected from the CHO cells with gentle pipetting.  
 
Cell lysate and nuclear extract preparation. Cells were treated as described in the 
figure legends. Following treatment, the cells were collected and centrifuged at 100 × g 
for 5 min. Medium was then aspirated, and cells were resuspended in PBS. The cell 
suspension was then divided into tubes, and whole cell lysates and nuclear extracts were 
subsequently prepared. Whole cell lysates were prepared using RIPA lysis buffer in a 
process that has been described previously (Kenneth et al., 2014). For the nuclear extract 
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preparation, cells were washed once with buffer A (10 mM HEPES, pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.1 mM PMSF, and 0.5 mM DTT) and pelleted by centrifugation at 
1500 × g for 1 min. The supernatant was aspirated, and the cell pellet was resuspended in 
15 µL of cold buffer A supplemented with 0.1% NP-40. The samples were incubated on 
ice for 5 min before being centrifuged at 16000 × g in a microfuge at 4°C for 15 min. The 
supernatant was removed, and the pellet was thoroughly resuspended in 10 µL of buffer 
C (20 mM HEPES, pH 7.9, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1 mM 
PMSF, 0.6 mM DTT, and 25% glycerol) and incubated at 4°C for 20 min with occasional 
mixing. The samples were then centrifuged at 16000 × g at 4°C for 15 min. The 
supernatant was transferred to a fresh tube containing 60 µL of modified buffer D (20 
mM HEPES, pH 7.9, 50 mM KCl, 0.2 mM EDTA, 0.1 mM PMSF, 0.5 mM DTT, and 
20% glycerol). The nuclear extracts were stored at -80°C. 
 
Immunoblot analysis. Protein concentrations of whole cell lysates were determined 
using a Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Lysates 
of equal protein concentrations were prepared in LDS sample buffer (Invitrogen, 
Carlsbad, CA, USA), separated on denaturing NuPAGE 4-12% polyacrylamide gradient 
gels (Invitrogen), and transferred to nitrocellulose membranes (GE Healthcare, 
Amersham, UK). Membranes were blocked in a 1:1 mixture of Odyssey blocking buffer 
(Li-Cor, Lincoln, NE, USA) and Tris-buffered saline (TBS). Membranes were then 
incubated with primary antibodies in a 1:1 mixture of Odyssey blocking buffer and TBS 
containing 0.1% Tween 20 (Fisher BioReagents, Waltham, MA, USA) overnight at 4°C. 
Following washing with TBS with 0.1% Tween 20, membranes were incubated with 
 63 
IRDye secondary antibodies (Li-Cor) for 1 h at room temperature. Membranes were then 
washed with TBS and analyzed using the Odyssey CLx infrared imaging system (Li-Cor) 
according to the manufacturer’s instructions. 
 
Electrophoretic mobility shift assays. Two complimentary oligonucleotides containing 
NF-κB consensus binding sites (5’-GATCCAGGGACTTTCCGCTGGGGACTTTCCA-
3’ and 5’-GATCTGGAAAGTCCCCAGCGGAAAGTCCCTG-3’) were annealed and 
radiolabeled using T4 polynucleotide kinase (New England BioLabs, Ipswich, MA, 
USA) in the presence of [γ-32P] ATP. The radiolabeled probe was then purified using 
illustra Microspin G-25 Columns (GE Healthcare) according to the manufacturer’s 
instructions. The presence of NF-κB in the nuclear extracts was assessed by incubating 2 
µL of the nuclear extract in modified buffer D without glycerol along with 1 µg of 
poly(dI-dC)poly(dI-dC), 1 µL of Bluejuice loading dye (Invitrogen), and 0.1 µL of the 
radiolabeled probe for a total volume of 20 µL. The prepared samples were then 
separated on a non-denaturing 4% polyacrylamide gel. Supershift assays were performed 
by adding 2 µL of antibodies against GST, p65, or RelB (Santa Cruz Biotechnologies) to 
the reaction mixture. Samples were incubated for 20 min at room temperature prior to 
running on the gel. For all assays, free probe was run off the gel to obtain maximum 
resolution. Autoradiography was conducted overnight at -20°C. 
 
Quantitative real-time PCR.  Cells were treated as indicated in the figure legends.  
Following treatment, the cells were washed with PBS, and total RNA was isolated using 
the RNeasy minikit (Qiagen, Valencia, CA, USA) according to the manufacture’s 
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instructions.  1 µg of total RNA was converted to cDNA using a reverse transcription 
reaction with random hexamer primers and MultiScribe Reverse Transcriptase (Applied 
Biosystems, Carlsbad, CA, USA).  1 µL of the resulting cDNA was analyzed for the 
indicated target genes using the ViiA 7 Real-Time PCR System (Applied Biosystems).  
Each target assay was normalized to β-actin or 18S levels. 
 
Transcriptome analysis by Bru-seq. Karpas 299 cells were incubated with the 
treatments indicated in the figure legends. To label nascent RNA, 2 mM bromouridine 
(Bru) was added to the media for the final 30 min of treatment time. The Bru-seq 
procedure has been previously described in detail (Paulsen et al., 2013; Paulsen et al., 
2014). Briefly, total RNA was collected from the treated cells using TRIzol reagent 
(Invitrogen), and the Bru-labeled, nascent RNA was isolated using anti-BrdU antibodies 
(BD Biosciences, San Jose, CA, USA) conjugated to magnetic beads (Invitrogen). The 
isolated RNA was converted into cDNA libraries, which were sequenced at the 
University of Michigan Sequencing Core using an Illumina HiSeq 2000 sequencer. The 
sequencing and read mapping were performed as previously described (Paulsen et al., 
2013; Paulsen et al., 2014). GSEA was used to identify up-regulated and down-regulated 
gene sets by determining which associated genes were significantly enriched in each gene 
set (Subramanian et al., 2005). The log fold change in expression of genes greater than 
1kb and expressed above 0.5 RPKM was used as the ranking metric by GSEA. The gene 
sets were obtained from version 4.0 of the Molecular Signatures Database 
(http://www.broadinstitute.org/gsea/msigdb/index.jsp). The gene sets used were 
canonical pathways (KEGG, Reactome, and BioCarta) and gene ontologies (biological 
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processes, molecular functions, and cellular compartment). Gene sets with FDR corrected 
P-values lower than 0.01 were considered to be significantly enriched and were used in 
the analysis. The primary sequencing data files from this study have been deposited in the 
NCBI Gene Expression Omnibus (GEO accession number: GSE64927). 
 
Measurement of protein synthesis. Cells were stimulated as indicated in the figure 
legends. Following the designated times, the cells were collected, and centrifuged at 100 
× g for 5 min. The supernatant was removed, and the cells were resuspended in L-
methionine free RPMI (Invitrogen) supplemented with 1 mM L-methionine or HPG (50 
µM final concentration), and were incubated at 37°C and 5% CO2 for 1 h. The cells were 
then harvested, washed with PBS, and fixed in 50% ice cold ethanol overnight at -20°C. 
The samples were then processed using the Click-iT HPG Alexa Fluor 488 Protein 
Synthesis Assay Kit (Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s instructions, and protein synthesis was measured by flow cytometry using 
an Accuri C6 flow cytometer (BD Biosciences). Relative rates of protein synthesis were 
calculated by normalizing the treated HPG sample to the control HPG sample after 
subtracting the auto-fluorescence background. 
 
Viability assays. Following the indicated treatments, cells were harvested, washed with 
PBS and subsequently resuspended in PBS with 2 µg/mL propidium iodide (PI). The cell 
viability of the PI-stained cells was assessed by flow cytometry using an Accuri C6 flow 
cytometer (BD Biosciences). 
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 CHAPTER III
Orchestration and Consequences of Canonical and Non-canonical NF-κB Activation 
by Synthetic IAP Antagonism 
 
Summary 
 Smac mimetics (SMs) have been shown to degrade the c-IAPs and activate NF-
κB, but are known to exhibit varying effects in different cellular contexts. To better 
understand the consequences of SM-induced signaling in different contexts, this signaling 
node was further investigated, finding that SM-induced activation of NF-κB was cell 
type-specific, and activation of canonical NF-κB corresponded to SM-induced cell death. 
Notably, p100 processing occurred in all tested cells, but nuclear, DNA-binding non-
canonical NF-κB was cell type-specific, suggesting that p100 processing is a poor 
surrogate marker for non-canonical NF-κB activation. Additionally, suppression of the 
non-canonical NF-κB subunit RelB resulted in a prolonged canonical NF-κB activation 
following extended treatment with SM, and this was associated with increased cell death 
and suppressed gene expression, collectively illustrating regulatory crosstalk between the 
two NF-κB signaling pathways. In contrast, prolonged SM treatment in cells possessing 
RelB resulted in gene expression and cell viability, suggesting that RelB-dependent gene 
expression was necessary to abrogate the DNA binding of canonical NF-κB. These 
results identify key consequences of both NF-κB signaling pathways, and further our 
understanding of the therapeutic potential of Smac mimetics. 
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Introduction 
As described in Chapter I, the c-IAPs are highly expressed in a variety of cancers, 
and amplification of the IAPs has been associated with poor survival outcomes in cancer, 
including colorectal, pancreatic, and cervical squamous cell carcinoma (Esposito et al., 
2007; Krajewska et al., 2005; Imoto et al., 2002). For these reasons, the c-IAPs are 
actively being investigated as potential therapeutic targets. A class of small molecule 
compounds based on the IAP binding protein, Smac, has been developed to target the 
IAPs. These Smac mimetics bind and induce the autoubiquitination and subsequent 
degradation of the c-IAPs, and this synthetic IAP antagonism has been demonstrated to 
result in cell death in a subset of cells (Vince et al., 2007; Varfolomeev et al., 2007; Lu et 
al., 2008). As discussed in Chapter I, these compounds have also been shown to activate 
NF-κB, a family of transcription factors that regulates genes involved in a variety of 
processes, including inflammation, cancer, and immune responses (Vince et al., 2007; 
Varfolomeev et al., 2007; DiDonato et al., 2012; Perkins, 2012). In mammalian cells, NF-
κB is comprised of five members, p65/RelA, RelB, c-Rel, NF-κB1 (p105/p50), and NF-
κB2 (p100/p52), that dimerize to form the active DNA-binding transcription factors 
(Ghosh and Hayden, 2012; Smale, 2012). 
The canonical NF-κB heterodimer p50:p65 has been extensively investigated 
(Vallabhapurapu and Karin, 2009), and activation of canonical NF-κB is triggered by a 
diverse set of stimuli, including DNA damage and stimulation of innate and adaptive 
immune receptors. As illustrated in more detail in Chapter I, prior to activation, the NF-
κB subunits are sequestered in the cytoplasm by the inhibitor of κB (IκB) proteins 
(Hayden and Ghosh, 2008), but upon stimulation, the IκB proteins are phosphorylated by 
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the IκB kinase (IKK) complex and targeted for ubiquitination, resulting in their 
proteasome-mediated degradation and the subsequent translocation of the NF-κB dimers 
into the nucleus to effect gene expression (Ghosh and Hayden, 2012). The c-IAPs 
mediate the activation of canonical NF-κB following stimulation of certain members of 
the tumor necrosis factor receptor (TNF) receptor superfamily, such as TNF-R1, and the 
absence of the c-IAPs induced by RNA interference or SM treatment abrogates signaling 
from these receptors, demonstrating a dependency on active c-IAP participation in this 
cascade (Varfolomeev et al., 2008). In contrast to TNF-R1-mediated signaling, SM-
induced NF-κB activation occurs in a receptor-independent manner through c-IAP 
degradation and modulation of NF-κB inducing kinase (NIK) protein levels, which has 
been shown to activate both canonical and non-canonical NF-κB (Malinin et al., 1997; 
Zarnegar et al., 2008).  
In contrast to our knowledge of canonical NF-κB activation, our understanding of 
the non-canonical NF-κB dimer p52:RelB is much less extensive. While canonical NF-
κB is activated by many stimuli, there are a more limited number of activators of non-
canonical NF-κB, and the best-characterized activators of this pathway are a subgroup of 
receptors within the TNF receptor superfamily that include CD30, CD40, and TNF-R2 
(Hacker et al., 2011; Wright et al., 2007; Wright and Duckett, 2009). As discussed in 
Chapter I, ligand binding causes these receptors to recruit and induce the degradation of 
TNF receptor-associated factor 2 (TRAF2), TRAF3, and c-IAP1/2 (Vallabhapurapu and 
Karin, 2009; Csomos et al., 2009; Vallabhapurapu et al., 2008). Prior to stimulation, c-
IAP1/2 inhibit non-canonical NF-κB activation by constitutively ubiquitinating and 
degrading NIK, but after their receptor-mediated degradation, NIK accumulates and 
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triggers phosphorylation of IKKα, which in turn phosphorylates p100, leading to the 
proteasome-dependent processing of p100 to the p52 form. The p52 subunit can then 
dimerize with RelB to form the active transcription factor (Vallabhapurapu and Karin, 
2009; Sun, 2012).  
In Chapter II, the consequences of two forms of IAP antagonism, SM treatment 
and CD30 activation, were compared, leading to the identification of novel functions for 
the c-IAPs, including regulation of protein synthesis (Kocab et al., 2015). While the 
studies in Chapter II compared CD30 and SM-induced NF-κB activation, previous work 
has connected NF-κB activation to SM-mediated cell death, illustrating that cells were 
either sensitive or resistant to SM-induced cell death and that this cell death was linked to 
NF-κB activation (Vince et al., 2007; Varfolomeev et al., 2007; Tenev et al., 2011; 
Petersen et al., 2007). Therefore, it was unclear if the findings in Chapter II would be 
universally observed in other cell lines. To address this, multiple cell lines were treated 
with the bivalent Smac mimetic, SM-164. The data presented in this chapter 
demonstrated that SM-induced c-IAP degradation results in cell specific consequences, 
and that SM-induced activation of canonical and non-canonical NF-κB was limited to a 
subset of cell lines. Furthermore, transcriptome analysis of SM-treated cells revealed 
major differences between the cell lines, potentially identifying novel consequences of 
SM treatment. Additionally, while not all cell lines activated non-canonical NF-κB 
following SM treatment, an effect that may be due to the absence of receptors or mutation 
of proteins in the signaling cascade, suppression of RelB in cells competent to activate 
non-canonical NF-κB resulted in a heightened sensitivity to SM-induced death, 
indicating that non-canonical NF-κB provided a protective advantage following SM 
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treatment. The protective effect conferred by non-canonical NF-κB stemmed from a 
modulation of the DNA binding of canonical NF-κB, and subsequent transcriptome 
analysis demonstrated that RelB was necessary to reverse the effects of SM-induced 
canonical NF-κB through the RelB-dependent expression of regulators of canonical NF-
κB. Collectively, the findings presented in this chapter identify key characteristics of 
non-canonical NF-κB, and further our understanding of the mechanism of SMs, as well 
as their therapeutic potential. 
 
Results 
Smac mimetic-induced NF-κB activation is cell type-specific and corresponds with 
cell death 
Smac mimetic treatment has been previously shown to induce NF-κB activation, 
which has been linked to SM-induced cell death (Varfolomeev et al., 2007; Vince et al., 
2007; Lu et al., 2008), and this earlier work with SMs collectively demonstrated that SM 
treatment either triggers cell death alone in some cell types, or sensitizes cells to TNF-
mediated cell death (Varfolomeev et al., 2007; Vince et al., 2007; Tenev et al., 2011; 
Petersen et al., 2007). In Chapter II, the outcomes of SM treatment were investigated in 
the anaplastic large cell lymphoma (ALCL) cell line Karpas 299, characterizing canonical 
and non-canonical NF-κB activation and identifying new functional aspects of c-IAP1/2 
(Kocab et al., 2015). To further investigate SM-induced NF-κB activation and its 
consequences, activation of NF-κB after SM treatment was assessed in multiple cell lines 
with varying sensitivity to SM-induced cell death (Tenev et al., 2011). The presence of 
nuclear, DNA-binding NF-κB following SM treatment was determined by electrophoretic 
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mobility shift assay (EMSA), and the results indicated that activation of NF-κB varied 
among the cell lines tested (Fig. 3.1A). Canonical NF-κB was robustly activated by SM 
treatment in the breast cancer cell line MDA-MB-231 and in Karpas 299 cells, but was 
not induced in HEK293 or in the colon cancer cell line HCT116. Additionally and in 
agreement with previously published reports, the treated cell lines exhibited differing 
degrees of sensitivity to SM-induced cell death (Fig. 3.1B) with cell death being observed 
in Karpas 299 cells and MDA-MB-231 cells, and resistance to SM-induced death being 
exhibited by HEK293 and HCT116 cells, indicating the requirement for additional 
stimuli to induce cell death in these cells. Taken together, these data support the proposed 
connection between canonical NF-κB activation and SM-induced cell death through the 
canonical NF-κB-dependent production of autocrine TNF (Vince et al., 2007; 
Varfolomeev et al., 2007). 
To further test the role of canonical NF-κB in promoting SM-induced cell death, 
MDA-MB-231 cells, which were sensitive to SM-induced death (Fig. 3.1B) and activated 
canonical NF-κB following SM treatment but not non-canonical NF-κB (Fig. 3.1A) were 
examined. SM treatment of MDA-MB-231 cells with suppressed expression of p65, a 
subunit of the canonical NF-κB dimer, resulted in higher viability as compared to the 
control cells, suggesting that activation of canonical NF-κB contributed to SM-induced 
cell death (Fig. 3.1C).  
While differences in activation of canonical NF-κB supported the previous reports 
describing that SM-induced cell death is dependent on canonical NF-κB (Vince et al., 
2007; Varfolomeev et al., 2008), differences in non-canonical NF-κB activation were 
also observed. While SM treatment has been previously shown to activate non-canonical 
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NF-κB as indicated by p100 processing (Varfolomeev et al., 2007; Vince et al., 2007), 
activation of nuclear, DNA-binding non-canonical NF-κB following SM treatment was 
found to be cell type-specific, as the SM-induced nuclear, DNA-binding non-canonical 
NF-κB RelB:p52 heterodimer was only observed in the Karpas 299 cells (Fig. 3.1A). To 
further investigate this, processing of p100 to p52, a major event following c-IAP1/2 
degradation that is widely used as a surrogate marker for non-canonical NF-κB activation 
(Vallabhapurapu et al., 2008; Csomos et al., 2009; Vince et al., 2007; Varfolomeev et al., 
2007), was assessed in order to determine if this event occurred globally or was also cell 
type-specific. In contrast to the EMSA data that illustrated the cell type-specific 
activation of non-canonical NF-κB, p100 processing was universally observed in the 
multiple cell types (Fig. 3.1D), suggesting that p100 processing was a poor surrogate 
assay for non-canonical NF-κB activation. Additionally, as expected, SM treatment 
triggered the degradation of c-IAP1 and c-IAP2, but, notably, did not degrade XIAP 
under the conditions used here (Fig. 3.1D), suggesting that the observed effects were due 
to the degradation of the c-IAPs and not due to XIAP degradation. Collectively, these 
data demonstrate that SM treatment results in nuclear, DNA-binding canonical and non-
canonical NF-κB in a cell type-specific manner. 
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Figure 3.1 SM-induced NF-κB activation is cell type-specific and corresponds 
with cell death 
A. HEK293, HCT116, MDA-MB-231, and Karpas 299 cells were treated with 100 nM 
SM-164 for 3 h or 500 U/mL TNF for 30 min. Nuclear extracts were prepared, and 
NF-κB was analyzed by EMSA. B. HEK293, HCT116, MDA-MB-231, and Karpas 
299 cells were treated with 100 nM SM-164 for the indicated time. Following 
incubation, cell viability was measured by propidium iodide (PI) exclusion and flow 
cytometry. C. MDA-MB-231 cells were transfected with siRNA targeting p65 or GFP 
(control). Cells were treated with 100 nM SM-164 for 24 h. Following treatment, 
whole cell lysates were prepared and analyzed by Western blot, and cell viability was 
measured using PI exclusion and quantitated by flow cytometry. D. HEK293, 
HCT116, MDA-MB-231, and Karpas 299 cells were treated with 100 nM SM-164 for 
3 h or 500 U/mL TNF for 30 min. Whole cell lysates were prepared and analyzed by 
Western blot using the specified antibodies. Can. NF-κB, canonical NF-κB; Non-can. 
NF-κB, non-canonical NF-κB; N.S., non-specific. 
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Gene expression profiles differ between cell lines following Smac mimetic treatment 
 While activation of NF-κB was found to be cell-type specific, it was unclear if 
this specificity was also applicable to the downstream consequences of SM treatment. To 
investigate the functional consequences of SM-induced NF-κB, a recently developed 
technique, Bru-seq, was employed to characterize the transcriptome of SM-treated cells 
through the analysis of newly transcribed RNA (Paulsen et al., 2013; Paulsen et al., 
2014). As described in Chapter II, Bru-seq was used to compare the outcomes receptor-
mediated and SM-induced c-IAP antagonism in Karpas 299 cells (Kocab et al., 2015), 
identifying novel consequences of IAP antagonism. To test if the effects observed 
following SM treatment were universal, HEK293 cells, which did not activate NF-κB 
following SM treatment (Fig. 3.1A), were treated with SM-164, and transcriptome 
profiles were generated by Bru-seq and compared to the Karpas 299 data. HEK293 cells 
were treated with SM in the same experimental conditions as for the Karpas 299 cells, 
incubated with bromouridine, and the resulting bromouridine-labeled RNA was isolated 
and converted into cDNA libraries, which were subsequently sequenced (Fig. 3.2A). The 
resulting data were compared to the previously published Karpas 299 data (Kocab et al., 
2015), and in the initial analysis, the change in gene expression in SM-treated HEK293 
was plotted against the change in gene expression in SM-treated Karpas 299 cells (Fig. 
3.2B). As expected, expression of established NF-κB target genes, such as NFKBIA, 
which encodes for IκBα, and BIRC3, the gene for c-IAP2, was barely changed in the SM-
treated HEK293 cells, but was highly increased in the Karpas 299 cells, which also 
exhibited activated NF-κB, indicating a role for NF-κB following SM treatment. As 
observed previously, SM treatment resulted in small changes in expression in a variety of 
 79 
genes in Karpas 299 and, perhaps more notably, in HEK293 cells (Kocab et al., 2015). To 
classify these genes and better understand the biological implications of their regulation, 
gene set enrichment analysis (GSEA) was performed, allowing for the characterization of 
groups of genes with modest expression changes using gene sets that have been 
established based on shared, biologically relevant characteristics (Subramanian et al., 
2005). Using this analysis allows for the identification of biologically significant 
processes involving genes with small changes in expression (Subramanian et al., 2005), 
and while the resulting GSEA data from SM-treated Karpas 299 cells showed a 
significant number of down-regulated gene sets (Kocab et al., 2015), SM-treatment 
resulted in the enrichment of numerous gene sets in HEK293 cells (Fig. 3.2C). Of the 
gene sets modified by SM treatment, the HEK293-specific sets involved RNA 
processing, suggesting that the c-IAPs may have a NF-κB-independent role in regulating 
RNA metabolism (Fig. 3.2D). Additionally, SM treatment did not affect gene sets related 
to NF-κB signaling and apoptosis regulation in HEK293 cells, as these were restricted to 
Karpas 299 cells (Fig. 3.2E), suggesting the necessity of NF-κB activation for regulation 
of these gene sets. There were, however, gene sets shared between the cell lines that were 
modified by SM treatment, but the enrichment of these gene sets was universally 
divergent (Fig. 3.2F). For example, Karpas 299 cells exhibited down-regulation of gene 
sets related to the ribosome and protein translation, as well as gene sets involved in 
metabolism. In contrast, these gene sets were all up-regulated in HEK293 cells following 
SM treatment, further emphasizing the cell type-specific effects of SM treatment and 
collectively illustrating key differences between cells that activate NF-κB and those that 
do not following SM treatment. 
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Suppression of RelB results in prolonged nuclear presence of SM-induced canonical 
NF-κB 
As described above, SM treatment exhibited cell type-specific effects, including 
NF-κB activation. However, the biological significance of non-canonical NF-κB 
activation remained unclear. To examine the role of this signaling pathway, expression of 
the non-canonical NF-κB subunit RelB was suppressed by siRNA in Karpas 299 cells, 
the only cell line tested that exhibited SM-induced non-canonical NF-κB activation. Non-
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Figure 3.2 Gene expression profiles differ between cell lines following Smac 
mimetic treatment 
A. Schematic of the Bru-seq experimental process. Karpas 299 and HEK293 cells 
were treated with 100 nM SM-164 for the indicated times. B. Plot of the Bru-seq data 
plotting the log2 fold change in gene expression from the SM-treated Karpas 299 
against the log2 fold change in gene expression of the SM-treated HEK293 cells. The 
location of the canonical NF-κB gene targets NFKBIA and BIRC3 are marked by red 
dots. C. Global depiction of the gene set enrichment analysis (GSEA) that reveals up- 
and down-regulated gene sets in the SM-treated cell lines. D-F. Examples of gene sets 
with false discovery rates (FDR) <0.05 that are regulated following SM treatment in 
HEK293 cells alone (D), in Karpas 299 cells alone (E), or regulated in both cell lines 
(F). The bars represent the normalized enrichment score for the indicated gene set. 
These experiments were performed with the help of Dr. Mats Ljungman and his lab. 
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canonical NF-κB was not observed in Karpas 299 cells with reduced RelB expression, 
but was strongly detected in the control cells following SM treatment (Fig. 3.3A). 
Notably, a significant level of nuclear, DNA-binding canonical NF-κB was identified in 
RelB-suppressed cells, suggesting that activation of non-canonical NF-κB modulates 
canonical NF-κB activity (Fig. 3.3A). A previously observed transition from canonical 
NF-κB to non-canonical NF-κB following SM treatment was described in Chapter II, 
indicating a potential regulatory role for non-canonical NF-κB (Kocab et al., 2015), and 
in support of this hypothesis, the data presented in chapter suggest that RelB is necessary 
for this transition. 
Since non-canonical NF-κB has been previously reported to impart a pro-survival 
phenotype (Gardam et al., 2011), the effect of reduced RelB expression on SM-induced 
cell death was consequently explored. SM treatment resulted in limited cell death in cells 
transfected with control siRNA, and the viability of these cells stabilized by 48 h of 
treatment. A similar initial decrease in cell viability was observed following SM 
treatment of cells with suppressed RelB expression, but decreased viability was observed 
at 48 h in these cells, thereby indicating that RelB promoted cell viability following SM 
treatment (Fig. 3.3B). The notion that non-canonical NF-κB provides a protective 
advantage was supported by a comparison of Karpas 299 cells to MDA-MB-231 cells, 
which do not activate non-canonical NF-κB and only activate canonical NF-κB following 
SM treatment (Fig. 3.1A). The Karpas 299 cells exhibited limited cell death at 24 h, but 
viability was unchanged at 48 h (Fig. 3.3C). In contrast, prolonged treatment with SM 
resulted in continued cell death in the MDA-MB-231 cells (Fig. 3.3C), and this pattern of 
cell death strongly resembled the death observed in the RelB-suppressed Karpas 299 cells 
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(Fig. 3.3B), suggesting a role for non-canonical NF-κB in promoting cell survival. 
Collectively, these data demonstrate that the absence of non-canonical NF-κB activation 
in cells sensitive to SM-killing results in a persistent DNA binding of nuclear, death-
promoting canonical NF-κB and continued susceptibility to SM-induced cell death. 
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RelB reverses the effects of SM-induced canonical NF-κB 
 To better understand the relationship between canonical and non-canonical NF-
κB following SM treatment, transcriptome analysis following prolonged treatment with 
SM was performed. RelB-suppressed Karpas 299 cells were treated with SM for 24 h in 
parallel with control cells. As expected, suppression of RelB prevented SM-induced non-
canonical NF-κB and resulted in a strong canonical NF-κB band observable by EMSA 
(Fig. 3.4A). Additionally, canonical NF-κB corresponded to down-regulation of gene sets 
as determined by GSEA in these samples (Fig. 3.4B), and many of these gene sets 
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Figure 3.3 Suppression of RelB results in prolonged nuclear presence of SM-
induced canonical NF-κB 
A. Karpas 299 cells were transfected with siRNA targeting RelB or GFP (control). 
Cells were then treated with 100 nM SM-164 for the indicated times. Nuclear extracts 
were prepared, and NF-κB was analyzed by EMSA. Over the course of the 
experiment, whole cell lysates were collected and were used to analyze RelB 
expression. B. Karpas 299 cells were transfect with siRNA targeting RelB or GFP 
(control). Cells were then treated with 100 nM SM-164 for the indicated times. Cell 
viability was measured by propidium iodide exlusion and flow cytometry. Whole cell 
lystates collected following treatment were analyzed for RelB expression levels. C. 
MDA-MB-231 and Karpas 299 cells were treated with 100 nM SM-164 for the 
indicated times. Following incubation, cell viability was measured by propidium 
iodide exclusion and flow cytometry. Can., canonical; Non-can., non-canonical; N.S., 
non-specific. 
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had also been down-regulated after 3 h of SM treatment (Fig. 3.2C, F), suggesting a 
potential inhibitory role for canonical NF-κB. In contrast to the cells with suppressed 
RelB expression, the GSEA results for the cells transfected with control siRNA were 
markedly different. These cells, which possessed RelB, had a multitude of up-regulated 
gene sets, many of which had been down-regulated in the RelB-suppressed cells (Fig. 
A.
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+
+ +
+ -
-
RelB
c-IAP1
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Non-can. 
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B.
siGFP siRelB
C.
siGFP
siRelB
Figure 3.4 RelB reverses the effects of SM-induced canonical NF-κB 
Karpas 299 cells were transfected with siRNA against RelB or GFP (control). The 
cells were treated with 100 nM SM-164 for 24 h. For the final 30 min of treatment, the 
cells were incubated with bromouridine in preparation for Bru-seq. A. Nuclear extracts 
were prepared from treated cells, and NF-κB activation was assessed by EMSA. B. 
Depiction of the GSEA from the Bru-seq results reveals the gene set regulation by 
RelB in the SM-treated cells. C. Example enrichment plots from the treated samples. 
The distribution of genes is listed according to rank position. FDR < 0.05. These 
experiments were performed with the help of Dr. Mats Ljungman and his lab. 
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3.4B). One example of this observation was the gene set for the structural constituents of 
the ribosome, which had a normalized enrichment score of 2.32 in the control cells, but in 
the RelB-suppressed cells, the normalized enrichment score was -1.89 (Fig. 3.4D), 
illustrating the divergent gene set regulation in the absence of RelB. Furthermore, the 
data presented in Chapter II showed that SM treatment can down regulate gene 
expression of ribosomal proteins and inhibit protein synthesis, postulating that this could 
contribute to SM-induced cell death (Kocab et al., 2015). The current data support the 
hypothesis that down-regulation of ribosomal gene sets resulted in sustained SM-killing, 
as the RelB-suppressed cells exhibited down-regulated ribosomal gene sets and increased 
sensitivity to SM-induced death. Overall, these data illustrate a role for non-canonical 
NF-κB in reversing the effects of SM-induced canonical NF-κB, thereby contributing to a 
pro-survival phenotype.  
 
RelB-dependent expression of regulatory factors abrogates nuclear, death-
promoting canonical NF-κB 
As described above, the presence of RelB abrogated the DNA binding of SM-
induced canonical NF-κB and its effects on gene regulation. In addition to this functional 
reversion of gene set regulation, cells with decreased RelB expression also exhibited 
long-term nuclear presence of the SM-induced canonical NF-κB dimer, but this did not 
result in significant gene expression (Fig. 3.5A). Conversely, gene expression was 
observed in the control cells that exhibited primarily non-canonical NF-κB following 24 
h of SM treatment (Fig. 3.5A), suggesting that RelB contributed to increased gene 
expression. Analysis of mRNA levels (Fig. 3.5B) and protein expression (Fig. 3.5C) 
showed decreased expression of the canonical NF-κB regulators A20 and IκBα in RelB-
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suppressed cells, demonstrating that these proteins were poorly expressed following 
suppression of RelB levels. These results suggest that RelB was responsible for gene 
expression that included the transcription of NF-κB regulatory factors, which are needed 
to inhibit SM-induced canonical NF-κB in the nucleus and thereby prevent increased cell 
death. Furthermore, these results highlight the crosstalk between the NF-κB pathways 
and illustrate a canonical NF-κB regulatory function for non-canonical NF-κB. 
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Figure 3.5 RelB-dependent expression of NF-κB regulatory factors abrogates 
nuclear, death-promoting canonical NF-κB 
A. Plot of the log2 fold change in gene expression of the siGFP control Karpas 299 
cells against the log2 fold change in gene expression of the siRelB cells following 24 h 
SM treatment. The location of TNFAIP3 and NFKBIA are marked by red dots. B. 
Karpas 299 cells were transfected with siRNA against RelB or GFP (control), and 
were subsequently treated with 100 nM SM-164 for 6 h. Following treatment, RNA 
was isolated and converted to cDNA, and the expression of the indicated genes was 
measured. C. Whole cell lystates from cells prepared as in B were collected and the 
expression of the indicated proteins was assessed by Western blot. 
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Discussion 
 In this chapter, the consequences of SM-induced NF-κB activation were 
investigated, and the results indicated that SM treatment resulted in different outcomes in 
a cell type-specific manner. More specifically, NF-κB activation was not universally 
observed, as canonical NF-κB activation was restricted to a subset of cell types, and the 
observation of non-canonical NF-κB activation was even more limited. These differences 
in NF-κB activation may be attributed to differential expression of other components in 
the signaling cascade. A scenario could be envisioned wherein cells that do not rely on 
physiological degradation of the c-IAPs for signaling would lack aspects of the 
downstream signaling cascade, potentially explaining why non-canonical NF-κB was 
only observed in Karpas 299 cells, a cell line that possesses a receptor that mediates 
physiological IAP antagonism. Notably, however, p100 processing to the active non-
canonical NF-κB subunit p52 was observed in all SM-treated cells. While this indicates 
that assaying p100 processing to p52 is not an optimal surrogate marker for non-
canonical NF-κB activation since it does not detect the presence of nuclear, DNA-binding 
NF-κB, it also elicits a provocative question regarding the function of p52: if SM-induced 
p100 processing is conserved across all cells, but activation of non-canonical NF-κB is 
cell type-specific, why is p100 processing to p52 universally observed? The pool of p52 
may be functionally inert in cells that lack the capacity to activate non-canonical NF-κB, 
but the possibility of p52 having a different role cannot be excluded. It has, for example, 
been reported that p52 homodimers can interact with p53 to repress or stimulate gene 
expression (Schumm et al., 2006). While the precise functions of p52 are still being 
defined, in the context of SM treatment and the absence of non-canonical NF-κB 
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activation, p52 may interact with other NF-κB subunits and proteins to modulate the 
expression of various genes and contribute to SM-mediated cell death, therefore 
representing intriguing avenues for future investigations. 
While SM treatment did not result in the universal activation of NF-κB, it still 
affected gene expression, indicating a transcriptional consequence of SM treatment that is 
independent of NF-κB signaling. SM treatment did not activate NF-κB in HEK293 cells, 
but it still resulted in minor changes in gene expression and up-regulation of certain gene 
sets. While it is unclear if this observed up-regulation of gene sets has a functional effect 
on cellular processes like proliferation and survival, it may suggest that c-IAP1/2 
degradation triggers additional signaling events that culminate in gene regulation. 
Alternatively, SM treatment may lead to consequences that are independent of its ability 
to induce the degradation of the c-IAPs and activate NF-κB. However, it remains to be 
seen if these effects are limited to HEK293 or whether they represent a more general 
mechanism of SMs. Notably, SM treatment resulted in divergent regulation of certain 
gene sets in HEK293 compared to Karpas 299 cells, and since Karpas 299 cells activated 
NF-κB following SM treatment and HEK293 did not, NF-κB may have an important role 
in regulating these genes. 
In cells that were competent to activate NF-κB, canonical NF-κB activation 
promoted cell death. The observation of a death-promoting canonical NF-κB supports the 
previously proposed mechanism of SM-mediated cell death, which is based on the 
canonical NF-κB-dependent production of TNF (Varfolomeev et al., 2007; Vince et al., 
2007; Petersen et al., 2007). In addition to its role in TNF production, canonical NF-κB 
may have additional, undiscovered functions, including the regulation of additional genes 
 90 
that may contribute to cellular fate, an idea that is supported by previous data showing 
that canonical NF-κB regulated the expression of both pro-apoptotic and pro-survival 
genes in the context of the DNA damage response (Campbell et al., 2004; Wu and 
Miyamoto, 2008). Additionally, while previous evidence indicates that receptor-mediated 
canonical NF-κB is activated by a different mechanism that is not dependent of c-IAP 
degradation (Duckett et al., 1997; Hacker et al., 2011; Matsuzawa et al., 2008), there 
have been reports of a NIK-dependent activation of canonical NF-κB through an IKKα-
mediated pathway (Zarnegar et al., 2008; A et al., 2000), suggesting a potential 
mechanism for SM-induced activation of canonical NF-κB signaling. It remains to be 
determined how these potential mechanistic differences in activation affect the gene 
targets and overall functionality of the resulting canonical NF-κB. 
In this chapter, bona fide non-canonical NF-κB activation was only observed in 
Karpas 299 cells, even though p100 processing was observed in all tested cell lines. This 
suggests that Karpas 299 cells, which express a receptor that mediates c-IAP degradation, 
possess a functional signaling cascade that may also include additional, unspecified 
cofactors that are required for full activation of non-canonical NF-κB. Furthermore, while 
previous work demonstrated that mice lacking the non-canonical NF-κB subunits had 
severe developmental defects of the secondary lymphoid organs, (Weih and Caamano, 
2003), the role of non-canonical NF-κB signaling remains poorly characterized. The data 
presented in this chapter demonstrated that the absence of non-canonical NF-κB 
prolonged the DNA binding activity of canonical NF-κB and coincided with continued 
SM-induced cell death, consequently indicating that non-canonical NF-κB exerts its 
protective effect, at least in part, by regulating the kinetics of canonical NF-κB through 
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the expression of canonical NF-κB regulators. This model could explain the observed 
pattern of SM-induced cell death in Karpas 299 cells as well as the kinetics of NF-κB 
activation described in Chapter II (Kocab et al., 2015): the initial cell death corresponded 
to early activation of canonical NF-κB, and by later time points, non-canonical NF-κB 
was fully activated and had replaced canonical NF-κB in the nucleus, inducing the 
expression of genes that inhibited the death signals and contributed to cell survival. 
Taken together, the results presented in this chapter provide evidence that the 
consequences of SM treatment are cell type-specific and, therefore, may have important 
therapeutic implications for SMs as they advance through clinical trials. By identifying 
and characterizing these differences, we may better understand how a SM therapeutic 
regimen may affect a patient and whether it should be used in combination with other 
drugs. It has already been established that targeting the c-IAPs may not be the best 
strategy for all cancers, as constitutive NF-κB signaling may promote survival and/or 
lead to a cytokine storm and systemic inflammation (Annunziata et al., 2007; Rosebeck et 
al., 2011; Rosebeck et al., 2014; Infante et al., 2014). In the context of the work presented 
in this chapter, assaying NF-κB activation in cells may predict the efficacy of the drug. 
Cells that do not activate NF-κB would be resistant to the therapy, while SM treatment 
may be most efficacious in cells that activate only canonical NF-κB since SM-induced 
canonical NF-κB promotes cell death. In contrast, in cells that also activate non-canonical 
NF-κB, the therapy may only have a limited effect as prolonged exposure to the drug may 
result in a non-canonical NF-κB-dependent pro-survival phenotype, potentially 
exacerbating the severity of the disease. In summary, these results collectively provide 
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valuable insight into the functionality of SM treatment and contribute to our 
understanding of their therapeutic value. 
 
Materials and Methods 
Cell lines and culture conditions. Human embryonic kidney (HEK) 293 cells were 
cultured in DMEM (Mediatech, Herndon, VA, USA) supplemented with 10% fetal 
bovine serum (FBS) and 2 mM L-glutamine. HCT116 cells were maintained in McCoy’s 
5A (Gibco, Carlsbad, CA, USA) medium supplemented with 10% FBS and 2 mM L-
glutamine. MDA-MB-231 cells were cultured in DMEM (Gibco) supplemented with 
10% FBS, 2 mM nonessential amino acids solution (Gibco), and 1% penicillin-
streptomycin (Gibco). Karpas 299 cells have been described previously (Mir et al., 2000) 
and were maintained in RPMI 1640 (Mediatech) medium supplemented with 10% FBS 
and 2 mM L-glutamine. All cells were cultured at 37°C in an atmosphere of 5% CO2. 
 
Materials. Human tumor necrosis factor (TNF) was purchased from Roche (Nutley, NJ, 
USA), and the siRNA transfection reagent INTERFERin was purchased from Polyplus 
Transfection (New York, NY, USA). The following primary antibodies were used in this 
study: anti-p100/p52 (Millipore, Billerica, MA, USA); anti-c-IAP1 and anti-XIAP (Enzo 
Life Sciences, Farmingdale, NY, USA); anti-c-IAP2 (Cell Signaling, Danvers, MA, 
USA); anti-RelB (Santa Cruz Biotechnology, San Diego, CA, USA); and anti-β-actin 
(Sigma-Aldrich, St. Louis, MO, USA). A FlexiTube GeneSolution containing small 
interfering RNAs (siRNAs) against RelB was purchased from Qiagen (Valencia, CA, 
USA) along with a control siRNA against GFP. The siRNA used in this study targeting 
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p65 has been previously described (Wright et al., 2007). SM-164 was a kind gift from Dr. 
Shaomeng Wang (University of Michigan). 
 
Cell lysate and nuclear extract preparation. Cells were treated as described in the 
figure legends. HEK293 cells were removed from the plate with gentle washing. Medium 
from HCT116 and MDA-MB-231 cells was collected, and the cells were washed with 
PBS and removed with trypsin, which was then inactivated using the collected medium. 
Karpas 299 cells were simply transferred to a conical tube. For all cell lines, cells were 
centrifuged at 100 × g for 5 min. Medium was then aspirated, and cells were resuspended 
in PBS. The cell suspension was then divided into tubes for different preparations so as to 
have corresponding whole cell lysates, nuclear extracts, and/or samples for viability 
assays. Whole cell lysates were prepared using RIPA lysis buffer (PBS containing 1% 
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease 
inhibitors. Incubation for 30 min on ice ensured complete lysis. For the nuclear extract 
preparation, cells were washed once with Buffer A (10 mM HEPES, pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.1 mM PMSF, and 0.5 mM DTT) and pelleted by centrifugation at 
1500 × g for 1 min. The supernatant was aspirated, and the cell pellet was resuspended in 
15 µL of cold Buffer A supplemented with 0.1% NP-40. The samples were incubated on 
ice for 5 min before being centrifuged at 16000 × g in a microfuge at 4°C for 15 min. The 
supernatant was removed, and the pellet was thoroughly resuspended in 10 µL of Buffer 
C (20 mM HEPES, pH 7.9, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1 mM 
PMSF, 0.6 mM DTT, and 25% glycerol) and incubated at 4°C for 20 min with occasional 
mixing. The samples were then centrifuged at 16000 × g at 4°C for 15 min. The 
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supernatant was transferred to a fresh tube containing 60 µL of modified Buffer D (20 
mM HEPES, pH 7.9, 50 mM KCl, 0.2 mM EDTA, 0.1 mM PMSF, 0.5 mM DTT, and 
20% glycerol). The nuclear extracts were flash frozen and stored at -80°C. 
 
Immunoblot analysis. Protein concentrations of whole cell lysates were determined by 
BCA. Lysates of equal protein concentrations were prepared in LDS sample buffer, 
separated on denaturing NuPAGE 4-12% polyacrylamide gradient gels (Invitrogen, 
Carlsbad, CA, USA), and transferred to nitrocellulose membranes (GE Healthcare, 
Amersham, UK). Membranes were blocked in a 1:1 mixture of Odyssey blocking buffer 
(Li-Cor, Lincoln, NE, USA) and Tris-buffered saline (TBS). Membranes were then 
incubated with primary antibodies in a 1:1 mixture of Odyssey blocking buffer and TBS 
containing 0.1% Tween 20 (Fisher BioReagents, Waltham, MA, USA) overnight at 4°C. 
Following washing with TBS with 0.1% Tween 20, membranes were incubated with 
IRDye secondary antibodies (Li-Cor) for 1 h at room temperature. Membranes were then 
washed with TBS and analyzed using the Odyssey CLx infrared imaging system (Li-Cor) 
according to the manufacturer’s instructions. 
 
Electrophoretic mobility shift assays. Two complimentary oligonucleotides containing 
NF-κB consensus binding sites (5’-GATCCAGGGACTTTCCGCTGGGGACTTTCCA-
3’ and 5’-GATCTGGAAAGTCCCCAGCGGAAAGTCCCTG-3’) were annealed and 
radiolabeled using T4 polynucleotide kinase (New England BioLabs, Ipswich, MA, 
USA) in the presence of [γ-32P] ATP. The radiolabeled probe was then purified using 
illustra Microspin G-25 Columns (GE Healthcare) according to the manufacturer’s 
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instructions. The presence of NF-κB in the nuclear extracts was assessed by incubating 2 
µL of the nuclear extract in modified buffer D without glycerol along with 1 µg of 
poly(dI-dC)poly(dI-dC), 1 µL of Bluejuice loading dye (Invitrogen), and 0.1 µL of the 
radiolabeled probe for a total volume of 20 µL. The prepared samples were then 
separated on a non-denaturing 4% polyacrylamide gel. Supershift assays were performed 
by adding 2 µL of antibodies against GST, p65, or RelB (Santa Cruz) to the reaction 
mixture.  Samples were incubated for 20 min at room temperature prior to running on the 
gel.  Autoradiography was conducted overnight at -20°C. 
 
Viability assays. Following the indicated treatments, cells were harvested, washed with 
PBS and subsequently resuspended in PBS with 2 µg/mL propidium iodide (PI). The cell 
viability of the PI-stained cells was assessed by flow cytometry using an Accuri C6 flow 
cytometer (BD Biosciences). 
 
Transcriptome analysis by Bru-seq. HEK293 or siRNA transfected Karpas 299 cells 
were incubated in the treatment conditions indicated in the figure legends. To label 
nascent RNA, 2 mM bromouridine (Bru) was added to the media for the final 30 min of 
treatment time. The Bru-seq procedure has been previously described in detail (Paulsen et 
al., 2013; Paulsen et al., 2014). Briefly, total RNA was collected from the treated cells 
using TRIzol reagent (Invitrogen), and the Bru-labeled, nascent RNA was isolated using 
anti-BrdU antibodies (BD Biosciences, San Jose, CA, USA) conjugated to magnetic 
beads (Invitrogen). The isolated RNA was converted into cDNA libraries, which were 
sequenced at the University of Michigan Sequencing Core using an Illumina HiSeq 2000 
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sequencer. The sequencing and read mapping were performed as previously described 
(Paulsen et al., 2013; Paulsen et al., 2014). GSEA was used to identify up-regulated and 
down-regulated gene sets by determining which associated genes were significantly 
enriched in each gene set (Subramanian et al., 2005). The log fold change in expression 
of genes greater than 1kb and expressed above 0.5 RPKM was used as the ranking metric 
by GSEA. The gene sets were obtained from version 4.0 of the Molecular Signatures 
Database (http://www.broadinstitute.org/gsea/msigdb/index.jsp). The gene sets used were 
canonical pathways (KEGG, Reactome, and BioCarta) and gene ontologies (biological 
processes, molecular functions, and cellular compartment). Gene sets with FDR corrected 
P-values lower than 0.01 were considered to be significantly enriched and were used in 
the analysis. The data generated from the HEK293 cells was compared to the published 
data with Karpas 299 cells and SM-164 (GEO accession number: GSE64927). The 
primary sequencing data files from this study will be submitted to the NCBI Gene 
Expression Omnibus upon acceptance of the manuscript. 
 
Quantitative real-time PCR.  Cells were treated as described in the figure legends.  
Following treatment, the cells were washed with PBS, and total RNA was isolated using 
the RNeasy minikit (Qiagen) according to the manufacture’s instructions.  1 µg of total 
RNA was converted to cDNA using a reverse transcription reaction with random 
hexamer primers and MultiScribe Reverse Transcriptase (Applied Biosystems, Carlsbad, 
CA, USA).  1 µL of the resulting cDNA was analyzed for the indicated target genes using 
the ViiA 7 Real-Time PCR System (Applied Biosystems).  Each target assay was 
normalized to 18S levels. 
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Transfections. Karpas 299 cells were transfected with siRNA using a Bio-Rad Gen 
Pulser II electroporator (Hercules, CA, USA) at 300 V and 975 µF. MDA-MB-231 cells 
were transfected with siRNA using the INTERFERin siRNA transfection reagent 
according to the manufacturer’s instructions. 
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 CHAPTER IV
Conclusions 
 
The IAPs were originally thought to mainly function as regulators of apoptosis 
through their direct inhibition of caspases (Salvesen and Duckett, 2002; Deveraux et al., 
1998; Liu et al., 2000), but over time, the IAPs have been implicated in numerous 
signaling pathways, indicating that they possess important functions unrelated to their 
originally described role in direct inhibition of apoptosis. The focus of this dissertation 
was on the regulation of signaling by the c-IAPs, ubiquitin ligases that have been 
previously shown to have contradictory roles in TNF receptor superfamily signaling 
(Silke and Brink, 2010). In the signaling cascades of certain receptors, such as TNF-R1, 
the c-IAPs have well-established roles in actively propagating the signal, leading to the 
activation of canonical NF-κB (Varfolomeev et al., 2008; Vince et al., 2009; Shu et al., 
1996). In contrast, the c-IAPs constitutively inhibit the activation of non-canonical NF-
κB through the degradation of NIK (Vallabhapurapu and Karin, 2009; Zarnegar et al., 
2008b), but upon activation of certain receptors, such as CD30, the c-IAPs are degraded, 
allowing for the activation of non-canonical NF-κB (Silke and Brink, 2010; Wright et al., 
2007; Csomos et al., 2009). Additionally, as discussed in Chapter I, degradation of the c-
IAPs can be induced by synthetic means, including treatment with a Smac mimetic 
(Vince et al., 2007; Varfolomeev et al., 2007; Darding et al., 2011). However, the 
downstream consequences of c-IAP activity have not been well defined, and it is also 
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unclear if synthetic and physiological forms of IAP antagonism are truly comparable. The 
findings presented in this dissertation reveal that the biological properties of c-IAP1/2 are 
context-dependent. Specifically, while receptor-mediated and Smac mimetic-induced c-
IAP degradation activated similar pathways and generated similar gene expression 
profiles, there were also substantial differences between the two stimuli, differences that 
will warrant future study. However, characterization of the similarities in the gene 
expression profiles following each stimulus revealed a novel function for the c-IAPs in 
the regulation of ribosomal gene expression and protein synthesis. Additionally, data 
presented in this dissertation demonstrated that SM-induced activation of NF-κB, an 
important outcome of c-IAP degradation, did not universally occur in all cell types, 
supporting the notion of context-dependent c-IAP1/2 activity. Due to the connection 
between NF-κB activation and SM-induced cell death, these findings also helped 
elucidate the mechanistic determinants of the efficacy of the drug, and may therefore 
have clinical impacts. 
 
Comparison of Physiological and Synthetic IAP Antagonism 
As described in earlier chapters, the canonical and non-canonical NF-κB 
pathways are activated by members of the TNFR superfamily and play important roles in 
the immune response, inflammation, and cancer (Walczak, 2011; Silke and Brink, 2010). 
A major aspect of Chapter II was to study the function of the c-IAPs in this context, as 
they have been shown to play important roles in the activation of NF-κB following 
activation of members of the TNFR superfamily. The c-IAPs have a demonstrated role in 
the activation of canonical NF-κB following TNF treatment (Varfolomeev et al., 2008; 
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Vince et al., 2009; Shu et al., 1996), and this contrasts with the receptor-induced 
degradation of c-IAP1/2 that is a required event in the activation of the non-canonical 
NF-κB pathway, a signaling cascade that physiologically occurs following activation of a 
limited subgroup of the TNFR superfamily, including CD30, CD40, and TNFR2 
(Vallabhapurapu and Karin, 2009; Zarnegar et al., 2008b). Additionally, Chapter II aimed 
to study c-IAP1/2 degradation by a class of synthetic, small molecule compounds called 
Smac mimetics (SMs), with the ultimate goal of comparing the physiological and 
synthetic forms of IAP antagonism in order to better understand the cellular roles of the 
c-IAPs. SMs, which are based on the IAP binding motif of Smac, bind to the c-IAPs and 
induce their autoubiquitination and subsequent degradation, resulting in NF-κB activation 
(Vince et al., 2007; Varfolomeev et al., 2007; Darding et al., 2011). While SM treatment 
has been shown to replicate aspects of receptor activation, it was unclear how extensively 
the consequences of SM treatment overlap with receptor-mediated degradation of the c-
IAPs. Therefore, to investigate this question, the work presented in Chapter II explored 
the consequences of IAP antagonism following physiological and synthetic stimuli. 
Through these studies, genes and pathways unique to each stimulus were identified, as 
were novel processes affected following both forms of c-IAP degradation. One 
commonality between the two inducers of c-IAP degradation was the down-regulation of 
genes related to the ribosome and translation, and further analysis demonstrated that this 
effect on gene expression led to a decrease in protein synthesis following each stimulus 
as well. These results potentially suggest an additional mechanism of SM killing, wherein 
SM-induced c-IAP degradation triggers the shutdown of protein synthesis, mimicking the 
 105 
effects of cycloheximide and rendering the cell more susceptible to TNF lethality (Fig. 
4.1). 
 
While both CD30 activation and SM treatment had an effect on protein synthesis, 
activation of the receptor did not affect protein synthesis as rapidly as SM treatment did. 
This may have been due to the ability of the receptor to activate additional signaling 
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Figure 4.1 Model of Smac mimetic-induced cell death. 
SM treatment results in the degradation of the c-IAPs, which activates NF-κB and 
leads to decreased gene expression of ribosomal proteins. Decreased gene expression 
of ribosomal proteins results in inhibited protein synthesis, mimicking the effect of 
cycloheximide and increasing the susceptibility to TNF-mediated cell death. While it 
is unclear if NF-κB has a role in regulating ribosomal gene expression, activation of 
NF-κB induces the production of autocrine TNF. Activation of TNF-R1 fails to 
activate NF-κB in the absence of the c-IAPs, preventing the expression of pro-survival 
factors and leading to TNF-R1-mediated cell death. Collectively, these events 
contribute to SM-induced cell death. 
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pathways, including the ERK signaling cascade. ERK has been shown to be a regulator of 
protein synthesis through its regulation of mTORC1 (Mendoza et al., 2011), and its early 
activation following CD30 stimulation may have countered any initial down-regulation of 
ribosomal genes induced by c-IAP degradation. As ERK signaling was eventually 
terminated, the signal balance would have shifted, resulting in the down-regulation of the 
ribosomal genes and potentially explaining the delayed observation of decreased protein 
synthesis following CD30 activation.  
 The data presented in Chapter II also hinted at a potential connection between c-
IAP degradation and cell cycle arrest, as the decrease in protein synthesis following 
CD30 activation was observed at 24 h, coinciding with previous reports of CD30-
mediated cell cycle arrest occurring at the same time point (Buchan and Al-Shamkhani, 
2012; Wright et al., 2007). Since there is an established connection between decreased 
protein synthesis and cell cycle arrest (Saracino et al., 2004; Verbin and Farber, 1967; 
Medrano and Pardee, 1980; Morinaga et al., 2008), the c-IAPs may regulate the cell cycle 
through their control of protein synthesis. In the context of CD30 signaling, c-IAP 
degradation-meditated cell cycle arrest may help control the expansion of activated T 
cells, preventing unchecked proliferation and preparing the cells for the contraction phase 
of the immune response by sensitizing the cells to death ligands. Additionally, if c-IAP 
degradation does regulate cell cycle, then future studies could focus on the effect of SMs 
on cell cycle, as it may represent another aspect of their mechanism. In the context of 
previous work illustrating that cell cycle-arrested cells are more sensitive to death-
inducing ligands, such as TNF and TRAIL (Darzynkiewicz et al., 1984; Lu et al., 2008a; 
Kuratnik et al., 2012; Jin et al., 2002; Ehrhardt et al., 2013), SM-induced cell cycle arrest 
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would increase the cell’s susceptibility to TNF-mediated death, a known component of 
SM-killing. Therefore, cell cycle arrest may be another mechanistic facet of SM 
treatment-induced cell death.  
While the data presented in this dissertation identified a novel role for the c-IAPs 
in the regulation of protein synthesis, the exact mechanism of how this occurs remains 
unresolved. Future studies may initially focus on the potential contributions of 
established regulators of protein synthesis and ribosome biogenesis, including mTOR, 
Myc, and Akt, during c-IAP degradation-mediated protein inhibition. Akt, for example, 
promotes protein synthesis and ribosome biogenesis through activation of mTORC1 
(Hsieh et al., 2011; Park et al., 2009; Mendoza et al., 2011), while Myc affects protein 
synthesis through the increased the expression of both rRNA and genes encoding 
ribosomal proteins (van Riggelen et al., 2010; Poortinga et al., 2015; Lempiainen and 
Shore, 2009). Notably, some of these known regulators of protein synthesis appear to 
have relationships with the IAPs. For example, expression of c-IAP2 and XIAP was 
increased by phosphatidylinositol 3-kinase (PI3K) and Akt following endoplasmic 
reticulum stress (Hu et al., 2004), and RIP1, an important ubiquitination target of the c-
IAPs, has been implicated in activation of the PI3K-Akt pathway (McNamara et al., 
2013; Park et al., 2009). In this context, degradation of the c-IAPs by CD30 or SM 
treatment may alter the ubiquitination of RIP1, affecting its ability to regulate the PI3K-
Akt pathway and having a downstream impact on protein synthesis. Additionally, 
overexpression of c-IAP1 has been shown to promote Myc activity through the 
ubiquitination and degradation of the Myc regulatory factor Mad1 (Xu et al., 2007), and 
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therefore, degradation of c-IAP1 could result in higher levels of Mad1 and result in the 
down-regulation of Myc-mediated ribosome biogenesis and protein synthesis. 
In addition to identifying how the c-IAPs regulate ribosomal gene expression and 
protein synthesis, future work may also explore the downstream consequences of 
decreased ribosomal protein gene expression. Specifically, down-regulation of these 
genes has been shown to affect the activity of microRNAs and their ability to associate 
with their target mRNA (Janas et al., 2012). Notably, decreased expression of ribosomal 
proteins resulted in an increase in translation of specific mRNAs, potentially contributing 
to a pro-tumorigenic effect (Janas et al., 2012; van Riggelen et al., 2010). Since inhibition 
of protein synthesis was observed with decreased ribosomal gene expression following 
CD30 activation and SM treatment, this previous work on miRNAs appears to contradict 
the data presented in this dissertation and therefore warrants future investigation.  
The data presented in Chapter II also implicated caspases in the regulation of the 
ribosomal gene expression, supporting the intriguing proposition that caspases have 
additional, non-apoptotic roles. While caspases are traditionally associated with the cell 
death signaling cascades, there is growing evidence of caspases having additional, non-
apoptotic roles as regulators of signaling. For example, in humans, caspase-1, -4, -5, and -
12 are considered inflammatory caspases and are involved in the innate immune response 
(Shalini et al., 2014). Caspase-1, more specifically, plays an important role in the 
processing and maturation of IL-1β during inflammation (Thornberry et al., 1992; 
Ghayur et al., 1997). Additionally, the apoptotic caspases have also been shown to 
possess apoptosis-independent functions. For example, caspase-3 plays a role in cell 
proliferation and differentiation, which may stem from its ability to regulate Akt 
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phosphorylation (Shalini et al., 2014; Fernando et al., 2002). Caspase-8, an important 
factor in apoptosis, has been implicated in the regulation of inflammation in a manner 
that is independent of apoptosis (Maelfait et al., 2008; Vince et al., 2012; Allam et al., 
2014), and has been shown to participate in the differentiation of monocytes into 
macrophages through the regulation of NF-κB via cleavage of RIP1 (Rebe et al., 2007; 
Kang et al., 2004). For these reasons, it would be interesting to examine the role of 
caspases in the context of SM-induced signaling. While preliminary data not shown in 
this dissertation indicated that SM-induced activation of NF-κB was independent of 
caspase activity, regulation of ribosomal gene expression and protein synthesis was 
dependent on caspases, suggesting potential downstream or co-regulatory roles for 
caspases in this system. However, while caspases play a role in SM-mediated signaling, 
the requirement of caspase activity in CD30 signaling has not been explored. 
Additionally, it would be interesting to identify the genes that are dependent on caspase 
activity for expression. Bru-seq experiments could be performed following treatment 
with chemical caspase inhibitors, such as z-VAD-fmk, or RNAi-mediated suppression of 
caspase expression to identify these genes and further clarify the role of caspases 
following IAP antagonism, as well as their relationship to NF-κB signaling.  
As previously discussed, the consequences of CD30 activation and SM treatment, 
while similar, possessed key differences, such as variances in kinetics and gene 
expression profiles. These differences may be due to additional pathways activated by 
CD30, unique genes regulated by the receptor, or a combination thereof. Conversely, SM 
treatment may also have unique effects that may contribute to the observed differences. 
One particularly noteworthy difference between the two stimuli is the mechanism of 
 110 
canonical NF-κB activation by the receptor. CD30, like its close TNF receptor 
superfamily relatives, is thought to activate NF-κB through its TRAF binding domains 
(Duckett and Thompson, 1997; Vallabhapurapu et al., 2008; Zarnegar et al., 2008b). 
However, it has also been previously demonstrated that CD30 possesses the ability to 
activate canonical NF-κB in the absence of its TRAF binding domains (Buchan and Al-
Shamkhani, 2012; Duckett et al., 1997), which would therefore be independent of c-IAP 
degradation. This raises the possibility that CD30 can activate multiple NF-κB pathways 
with undefined functions (Fig. 4.2). These pathways may not be replicated by SM 
treatment, as SM-induced canonical NF-κB appears to be due to c-IAP degradation and is 
most likely dependent on the accumulation of NIK, a protein normally associated with 
non-canonical NF-κB activation but also has a reported ability to activate canonical NF-
κB (Malinin et al., 1997; Zarnegar et al., 2008a). These differences may explain the 
observable canonical NF-κB following prolonged CD30 stimulation that is absent after 
extended SM treatment, as well as the observed transcriptome profile disparities between 
CD30 activation and SM treatment. 
 To explore the possibility that CD30 can activate multiple NF-κB signaling 
pathways, genome-editing techniques, such as TALENs or CRISPR/Cas, could be used to 
generate CD30 mutants possessing truncated cytoplasmic tails. Using genome-editing 
techniques in an anaplastic large cell lymphoma cell line, such as Karpas 299, would 
generate a system wherein the endogenous, full-length CD30 would be absent. However, 
the downstream machinery for CD30 signaling would remain intact, which is an 
important consideration since not all cells appear to possess the ability to activate these 
pathways, as illustrated in Chapter III. Studying these new cell lines using the same 
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techniques discussed in Chapter II would provide valuable insight into the requirement of 
each domain of CD30 for the observed consequences of receptor activation, including as 
c-IAP degradation, TRAF degradation, MAPK activation, NF-κB activation, cell cycle 
arrest, protein synthesis, and cell death. Furthermore, performing Bru-seq experiments 
with the CD30 mutants may help identify exactly which aspects of receptor signaling SM 
treatment can mimic. 
 
 
Canonical NF-κB
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Figure 4.2 Model of the three phases of CD30-mediated NF-κB activation. 
Canonical NF-κB (1) is observed rapidly after receptor activation (~15 min). 
Activation of this canonical NF-κB is independent of the TRAF binding domains 
within the cytoplasmic tail of CD30 and is independent of c-IAP1/2 degradation. 
Occurring in parallel, the c-IAPs are degraded, mimicking the effects of SM treatment. 
This triggers the induction of a second canonical NF-κB (2), which is observed 
approximately 1 h after receptor activation. Lastly, non-canonical NF-κB (3) is 
observed approximately 3 h following initial stimulation. 
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Since the data suggest that CD30 activates multiple NF-κB pathways, future 
experiments may aim to characterize these NF-κB complexes and investigate their 
functions. CD30 appears to have the potential to activate at least two distinct canonical 
NF-κB complexes, one dependent on c-IAP degradation and one independent of c-IAP 
degradation (Fig. 4.2). While these NF-κB complexes may both be comprised of p65 and 
p50, these subunits may possess different modifications and downstream functions. In 
support of this idea, previous work has demonstrated that the subunits of NF-κB could be 
differentially modified by phosphorylation, methylation, and acetylation, and that these 
modifications affected the activity and gene targets of the NF-κB dimer (Viatour et al., 
2005; Chen and Greene, 2003; Bhatt and Ghosh, 2014; Diamant and Dikstein, 2013; Lu 
et al., 2013; Chen et al., 2002). As an example, the canonical NF-κB subunits, p65 and 
p50, can be phosphorylated on multiple serine residues, resulting in enhanced DNA-
binding and transactivation potential (Viatour et al., 2005). Identifying these 
modifications would be the first step in connecting each modification with specific gene 
signatures, as identified by Bru-seq or another sequencing technique. Additionally, the 
CD30 tail mutants discussed above would allow for the investigation into the necessity of 
each domain of CD30 for the modifications of NF-κB, helping to clarify the exact 
mechanism of CD30-mediated signaling. Furthermore, comparing the modifications of 
SM-induced NF-κB to the CD30 results, along with data from experiments using RNAi-
mediated suppression of NIK, c-IAPs, and TRAFs, would help identify which factors and 
domains are needed for each modification of NF-κB. Once the outcomes of these 
experiments have been established, testing if the signaling from a truncated CD30 could 
be rescued by SM treatment would help assess the accuracy of the resulting model.  
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While differences in signaling pathway activation may help explain the variances 
between CD30 activation and SM treatment, another potential contributing factor could 
be differences in downstream gene expression, as highlighted by the Bru-seq results in 
Chapter II. There were gene sets uniquely regulated by each of the stimuli, and these 
differences warrant future study since they may have contributed to the variances 
observed between the two stimuli. Furthermore, the Bru-seq results contain additional 
data that would be worthy of future investigation, including the observed down-
regulation of gene sets related to cellular energetics and metabolism following both CD30 
activation and SM treatment. While this preliminary data does not specify how this gene 
regulation affects the metabolic programming within the cell, it may have important 
biological implications. T cells, for example, exhibit metabolic reprogramming during 
their activation and differentiation (Palmer et al., 2015; Wang and Green, 2012), 
switching from primarily oxidative phosphorylation in their naïve state, to glycolysis 
upon activation (Macintyre et al., 2014; Verbist et al., 2012). Since CD30 has been 
associated with activated T cells (Del Prete et al., 1995; Nakamura et al., 1997; Croft, 
2003), these data potentially suggest a specific role for the receptor during T cell 
activation. Additionally, as cancer cells generally rely on glycolysis for energy 
metabolism (Hsu and Sabatini, 2008; Jones and Thompson, 2009; Hanahan and 
Weinberg, 2011), future studies investigating the effects of SM treatment on cellular 
energetics may find that IAP antagonism alters or reprograms the metabolism of the cell, 
contributing to SM-induced cell death.  
Since the c-IAPs are involved in NF-κB activation by other receptors, such as 
BAFF-R and CD40, future studies may explore if the results of this dissertation are more 
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widely applicable (Vallabhapurapu et al., 2008; Gardam et al., 2011). Other members of 
the TNF receptor superfamily have been shown to degrade the c-IAPs and subsequently 
activate NF-κB following ligand binding (Vallabhapurapu et al., 2008); yet the similarity 
of the downstream effects of NF-κB activation by these receptors is unclear. While these 
receptors are thought to activate NF-κB through the TRAF-binding domains of their 
cytoplasmic tails, the structure of these regions of the receptors differ (Mosialos et al., 
1995; Lee et al., 1996; Boucher et al., 1997; Ishida et al., 1996; Lu et al., 2003), and it 
remains unclear how these structural differences affect the activation of NF-κB and 
downstream gene expression. Would CD40, for example, also affect protein synthesis in 
a manner similar to CD30? Comparing multiple receptors to the CD30 data presented in 
this dissertation would provide a stronger understanding of the functional consequences 
of NF-κB activation.  
One comparison that was not explored in this dissertation was the mechanistic 
differences in IAP degradation by SM treatment and CD30 activation. Specifically, SM 
treatment does not degrade TRAF2, while CD30 activation does (Csomos et al., 2009; 
Wright et al., 2007), and the consequences of a pool of unbound TRAF2 remain 
unknown. Furthermore, SMs have been shown to interact with XIAP, a protein not 
associated with CD30 signaling (Vince et al., 2007; Varfolomeev et al., 2007; Sun et al., 
2007; Lu et al., 2008b), and it is unclear how this interaction may affect the observed 
downstream consequences. Even if XIAP is not degraded, SM may still functionally 
inhibit it, potentially contributing to the observed differences between the two stimuli. 
Additionally, CD30-mediated degradation of the c-IAPs is dependent on the RING 
domain of TRAF2, but does not require the E3 ubiquitin ligase activity of c-IAP1 
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(Csomos et al., 2009), while SM-induced degradation of the c-IAPs, conversely, is 
dependent on the E3 ubiquitin ligase activity of c-IAP1 (Csomos et al., 2009), indicating 
that the mechanics of ubiquitination and degradation also differ between the two stimuli. 
However, the experiments that identified these differences were performed in HEK293 
cells and did not account for c-IAP2, suggesting the potential need to repeat these 
experiments in Karpas 299 cells using genome-editing techniques to generate the 
appropriate TRAF and c-IAP mutants. This system would eliminate the wild type TRAF 
and c-IAP proteins and would provide a competent cellular system in which to 
investigate downstream signaling.  
 
Synthetic IAP Antagonism and NF-κB 
As discussed in earlier chapters, the IAPs have been implicated in the progression 
of cancer, and elevated expression of IAPs has been associated with poor survival rates 
(Xiang et al., 2009; Hussain et al., 2010; Esposito et al., 2007; Krajewska et al., 2005; 
Imoto et al., 2002). For these reasons, research has focused on means to inhibit the IAPs 
as a potential therapeutic strategy against cancer, leading to the development of SMs, 
which bind and induce the autoubiquitination and subsequent degradation of the IAPs 
(Vince et al., 2007; Varfolomeev et al., 2007; Darding et al., 2011), resulting in cell death 
in certain cells or sensitization of cells to exogenous TNF-mediated cell death (Petersen 
et al., 2007; Tenev et al., 2011). While the ability to induce cell death is promising for an 
anti-cancer therapeutic, SMs have also been shown to induce both canonical and non-
canonical NF-κB activation, events normally considered to be pro-survival (Beinke and 
Ley, 2004; Beg et al., 1995; Vince et al., 2007; Varfolomeev et al., 2007). In contrast to 
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the pro-survival function typically associated with NF-κB, previous work with SMs has 
indicated that SM-induced cell death is dependent on NF-κB signaling, thereby 
suggesting a potential multifaceted role for NF-κB following c-IAP antagonism (Vince et 
al., 2007; Varfolomeev et al., 2007). To investigate this notion, the aim of Chapter III 
was to characterize SM-induced NF-κB activation and explore its functional 
consequences in different cellular contexts, and the resulting data demonstrated that SM-
induced NF-κB activation is cell type-specific. Specifically, while canonical NF-κB was 
observed in a limited number of cell types, activation of non-canonical NF-κB was 
restricted to Karpas 299 cells, even though p100 processing to p52, a widely used 
surrogate marker of non-canonical NF-κB activation, was observed in all treated cells 
(Fig. 4.3). Functionally, SM-induced canonical NF-κB was found to promote cell death, 
complementing previous work that described a death-promoting canonical NF-κB 
complex (Campbell et al., 2004; Wu and Miyamoto, 2008). In contrast, activation of non-
canonical NF-κB was found to promote cell survival through the inhibition of death-
promoting canonical NF-κB. Suppression of non-canonical NF-κB was found to result in 
prolonged DNA binding of canonical NF-κB in the nucleus, and, notably, the presence of 
this transcription factor inhibited gene expression and resulted in the continued down-
regulation of multiple gene sets. Non-canonical NF-κB reversed these effects and 
resulted in increased gene expression and up-regulation of numerous gene sets, indicating 
that non-canonical NF-κB functions, in part, as a regulator of canonical NF-κB, thereby 
preventing further SM-induced cell death (Fig. 4.3).  
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While much of the data presented in Chapter III relates to the consequences of 
SM-induced NF-κB activation, one notable finding suggested that SM treatment might 
have additional effects, independent of NF-κB signaling. Gene expression in HEK293 
cells was affected by SM treatment, even though these cells did not activate NF-κB. 
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Figure 4.3 Model of canonical and non-canonical NF-κB activation following SM 
treatment. 
SM-induced degradation of the c-IAPs initially results in a cell type-specific activation 
of canonical NF-κB. This NF-κB complex promotes death through the production of 
autocrine TNF, which results in TNF-R1-mediated cell death. Furthermore, SM-
induced canonical NF-κB may be involved in the down-regulation of ribosomal gene 
expression, sensitizing the cell to TNF-mediated cell death. Additionally, c-IAP 
degradation results in the processing of p100 to p52, one subunit of the active non-
canonical NF-κB dimer. This event was observed in every cell line treated with SM. 
Observation of nuclear, DNA-binding non-canonical NF-κB, however, was cell type-
specific. This NF-κB dimer promoted cell survival and regulated canonical NF-κB. 
Non-canonical NF-κB was found to reverse the effects of canonical NF-κB and induce 
the expression of numerous genes, including inhibitors of canonical NF-κB. 
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While this may have been a cell type-specific event, these data suggest that SM treatment 
results in additional undefined consequences. Future studies may investigate if these 
effects occurred in other cells, potentially through monitoring gene expression following 
NF-κB inhibition and SM treatment. Observation of gene expression under these 
conditions would indicate that SM also regulates gene expression through NF-κB-
independent means. Additionally, the observed gene expression patterns in HEK293 
cells, as well as the other findings presented in Chapter III, may have been due to 
potential off target effects of the SM, rather than c-IAP degradation. Comparing the 
effects of multiple SMs, both monovalent and bivalent forms, could test this idea, as 
could RNAi-mediated suppression of c-IAP expression and ectopic expression of Ub-
Smac, an engineered form of Smac that bypasses the mitochondria and is present in the 
cytoplasm in the absence of apoptotic stimuli (Hunter et al., 2003). Common 
consequences that were observed under these conditions would more clearly define the 
role of IAP antagonism in signaling. 
While the focus of this dissertation was on the c-IAPs, SM treatment has been 
shown to also target XIAP for degradation (Darding et al., 2011; Lu et al., 2008b; Vince 
et al., 2007; Varfolomeev et al., 2007), even though XIAP was not degraded under the 
conditions used in studies presented in this dissertation. Even though XIAP was not 
degraded, the possibility that SM treatment still results in the functional inhibition of 
XIAP cannot be excluded. Future studies that aim to better characterize the role of XIAP 
in this context may use immunoprecipitation to monitor the association of XIAP with 
caspases before and after treatment with SM-164. Parallel experiments may use 
biotinylated forms of SMs, which currently exist, to see if the SM interacts with XIAP in 
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the conditions used in these studies. Additionally, there have also been recent reports of 
SMs that specifically target c-IAP1/2 (Sun et al., 2014), and the use of these compounds 
would provide insight into the necessity of XIAP in the signaling pathways described in 
Chapters II and III. While these experiments would help separate the functions of XIAP 
and the c-IAPs, it may also be useful to discern the individual roles of c-IAP1 and c-
IAP2. While the c-IAPs are often considered redundant, there is evidence that they 
possess non-redundant roles, as well (Darding et al., 2011). Furthermore, the two c-IAPs 
appear to have varying expression following certain stimuli, with c-IAP2 being highly 
expressed following NF-κB activation while c-IAP1 is not, and this disparity may 
underlie functional differences between the two proteins. Additionally, while c-IAP1 
appears to be expressed in the cell lines tested in Chapter III, the expression of c-IAP2 
varied between the cell lines, suggesting differential regulation and, perhaps, functional 
importance. Future experiments that target the individual c-IAPs with RNAi would help 
answer these questions, though the results from experiments using the Smac mimetic, 
Birinapant, in Chapter II suggest that efficient degradation of both c-IAPs is necessary for 
SM-induced NF-κB activation.  
Physiologically, IAP antagonism can occur during the cell death process when 
IAP binding proteins, such as Smac, are released from the mitochondria. However, as 
proteins typically associated with cell death, such as the IAPs and caspases, are 
implicated in signaling pathways other than apoptosis, it is possible that Smac also has 
non-apoptotic roles. Could Smac be a regulator of IAP and caspase activity in the 
absence of a death stimulus? In support of this idea, there have been reports of selective 
release of Smac from the mitochondria under certain conditions (Kandasamy et al., 2003; 
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Csomos et al., 2009). Furthermore, data not presented in this dissertation, along with 
previous work, have demonstrated that suppression of Smac expression by siRNA 
resulted in decreased baseline gene expression, suggesting that Smac may have non-
apoptotic, housekeeping roles within a cell (Csomos et al., 2009). 
While the results presented in Chapter III compared the effects of SM treatment in 
multiple cells, the limitation of the data being based on established cell lines remains. 
Since primary cells were not used in these studies, it is unclear if the c-IAPs play the 
same role in both cancer cells and healthy cells, leading to the question of whether 
primary samples from cancer patients and healthy controls would behave similarly. 
Future experiments that explore this question could compare healthy T cells to the Karpas 
299 data presented in this dissertation, specifically focusing on both CD30 and SM-
mediated c-IAP degradation, NF-κB activation, p100 processing, and cell death. If these 
events are also observed in the healthy T cells, additional assays investigating gene 
expression and protein synthesis may be warranted. Eventually, performing these assays 
in primary cells from cancer patients would help better convey the clinical relevance of 
the findings of this dissertation. 
Since cancer cells proliferate rapidly, future studies may investigate and compare 
the effect of SM treatment in quiescent cells and rapidly proliferating cells, potentially 
monitoring cell cycle progression, which may be important in the context of c-IAP 
degradation since CD30 activation was found to induce cell cycle arrest (Buchan and Al-
Shamkhani, 2012; Wright et al., 2007), though it is unclear if this directly resulted form 
IAP degradation. Additionally, in certain cells, such as HeLa and THP1, c-IAP1 was 
found to localize to the nucleus and was implicated in the regulation of cell cycle 
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progression (Xu et al., 2007; Samuel et al., 2005; Cartier et al., 2011; Plenchette et al., 
2004), suggesting that SM-induced c-IAP degradation could induce cell cycle arrest. If 
SM treatment does lead to cell cycle arrest, this may mean that SMs are more effective in 
rapidly dividing cells, such as cancer cells, and may have a more limited effect in slow 
growing cells, potentially differentially targeting cancer cells over surrounding tissue. In 
addition to comparing the effects of SM treatment in healthy cells with cancer cells, 
quiescent T cells could be compared to activated and proliferating T cells. Collectively, 
these experiments would provide a better characterization of the optimal targets of SM 
treatment as well as how these compounds could affect other tissues in patients.  
Another unresolved aspect of the work presented in this dissertation is the 
mechanistic basis for the observed variances in NF-κB activation following SM treatment 
in the different cell lines. The absence of NF-κB activation may be explained by the lack 
of functional upstream factors, either through differential expression or mutations. 
Mutations in NIK, for example, have been described, and these mutations result in 
defective canonical and non-canonical NF-κB signaling (Willmann et al., 2014). Future 
experiments may initially compare the different cell lines in more detail, examining, for 
example, the status of IκBα and the IKK complex, degradation of NIK, localization of the 
NF-κB dimers, and modifications of the NF-κB subunits. Once potential differences are 
identified, it would be interesting to determine if a correlation between functional NF-κB 
signaling and expression of TRAF-binding TNF receptor superfamily members exists, as 
these have restricted expression and induce activation of both NF-κB pathways. Future 
studies may also choose to investigate the function of p52 since SM treatment induced 
the processing of p100 to p52 in all the tested cell lines, yet DNA-binding non-canonical 
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NF-κB was not observed in the majority of the cells. Since the processing event occurred 
in all cells, it may imply that p52 has other roles, independent of its participation in the 
non-canonical NF-κB dimer. Investigating the functional consequences of the pool of p52 
may identify additional functions and help us further understand the dynamics of NF-κB 
signaling.  
With the work presented in Chapter III, a role for RelB in the regulation of 
canonical NF-κB was illustrated. However, as this experiment was only performed using 
SM treatment, it is unclear how this would impact CD30 signaling. In Chapter II, the 
kinetics of NF-κB activation following CD30 stimulation were found to differ from the 
outcome of SM treatment. While a gradual shift from canonical NF-κB to non-canonical 
NF-κB was observed following SM treatment, CD30 stimulation resulted in a consistent 
nuclear presence of canonical NF-κB. The observable canonical NF-κB following 
prolonged stimulation with CD30L is most likely a mixture of differentially activated 
canonical NF-κB, specifically c-IAP degradation-dependent and -independent forms that 
may possess divergent modifications and functionality, and this may represent a distinct 
outcome compared to SM treatment, which appears to activate a single, c-IAP 
degradation-dependent canonical NF-κB signaling pathway. Due to the technical 
limitations of EMSAs, it is unclear if the observed canonical NF-κB band is comprised of 
more than one form of canonical NF-κB, i.e. c-IAP degradation-dependent and -
independent canonical NF-κB. Therefore, if the experiments proposed above could 
identify multiple, differentially modified canonical NF-κB dimers following the various 
treatment conditions, it would be interesting to further investigate the role of RelB in this 
system. Would RelB preferentially regulate a specifically modified form of canonical 
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NF-κB? Would the ratio of the modified forms of canonical NF-κB be altered following 
suppression of RelB expression? Suppression of RelB expression by RNAi techniques in 
Karpas 299 cells followed by stimulation with CD30L and monitoring of NF-κB 
activation and gene expression would help answer these questions and provide valuable 
information into how the transcriptional outcomes following prolonged CD30 activation 
were affected by RelB and non-canonical NF-κB.  
As this work is expanded beyond the Karpas 299 cellular system, studying both 
canonical and non-canonical NF-κB signaling cascades in other cellular contexts may be 
important as both pathways are activated throughout the development of the immune 
system and during its response to antigenic challenge (Oeckinghaus et al., 2011; 
Vallabhapurapu and Karin, 2009). As the work presented in Chapter III helped define a 
novel functional role for non-canonical NF-κB, it may be important to examine if non-
canonical NF-κB regulates canonical NF-κB in these other cellular contexts, as well as in 
certain cancers. More specifically, both NF-κB pathways are activated in multiple 
myeloma and MALT lymphoma (Rosebeck et al., 2014; Rosebeck et al., 2011; 
Annunziata et al., 2007), and therefore if non-canonical NF-κB confers a pro-survival 
phenotype in these cells, blocking activation of non-canonical NF-κB may be needed for 
effective anti-cancer therapies. 
As described above, NF-κB can be frequently modified, affecting its activity and 
gene targets (Viatour et al., 2005; Chen and Greene, 2003; Bhatt and Ghosh, 2014; 
Diamant and Dikstein, 2013; Lu et al., 2013; Chen et al., 2002). While the modifications 
of SM-induced NF-κB are presently unknown, future experiments may aim to investigate 
potential cell type-specificity of these modifications. Is SM-induced canonical NF-κB the 
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same in different cellular contexts? If so, it would imply that these cells have the proper 
machinery to perform the modifications, leading to an active NF-κB dimer, highlighting 
potential factors that may be absent in other cell lines. If the observed canonical NF-κB 
dimers were to be modified differently, how would this impact their function? The 
answer to this question would provide additional information on the mechanism of SMs 
and help more effectively guide their use in the clinic.  
 
Closing Remarks 
In conclusion, the work presented in this dissertation examined the roles of the c-
IAPs in intracellular signaling, identifying novel aspects of c-IAP-dependent signaling 
through the comparison of the functional consequences of physiological and synthetic c-
IAP antagonism. The findings presented in this dissertation established a new role for the 
c-IAPs in the regulation of protein synthesis and also demonstrated that the downstream 
effects of IAP antagonism were partially stimulus-dependent. Furthermore, the data 
presented in this dissertation described the cell type-specific nature of SM-induced NF-
κB activation and identified regulatory crosstalk between canonical and non-canonical 
NF-κB. Collectively, the data from Chapters II and III lay a solid foundation for future 
studies, and contributes to our understanding of the multifaceted roles of c-IAP1/2 in 
cellular signaling and provides valuable insight into the mechanism of synthetic IAP 
antagonists, furthering our understanding of their therapeutic potential. 
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